{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:08:35Z","timestamp":1793210915725,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006023.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000}}],"reference-count":743,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006023.pub4","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T06:29:53Z","timestamp":1751005793000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)"],"prefix":"10.1002","volume":"2025","author":[{"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Ruospo","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"},{"name":"College of Medicine and Public Health; Flinders University; Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Vecchio","sequence":"additional","affiliation":[{"name":"Danone Research; Palaiseau Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grahame J","family":"Elder","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine; Westmead Hospital; Westmead Australia"},{"name":"University of Notre Dame Australia; School of Medicine; Sydney Australia"},{"name":"University of Sydney; Faculty of Medicine and Health; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari; Bari Italy"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0001|cit1","first-page":"769","article-title":"Comparative efficacy of sevelamer hydrochloride versus calcium acetate on bone biomarkers in patients with end stage renal disease on hemodialysis","volume":"8","author":"Ahmed","year":"2014","journal-title":"Pakistan Journal of Medical & Health Sciences"},{"issue":"Sept","key":"10.1002\/14651858.CD006023.pub4-BIB0002|cit2","first-page":"557A","article-title":"Effect of sevelamer hydrochloride (PB-94) on hyperphosphatemia in Japanese hemodialysis (HD) patients [abstract no: A2940]","volume":"11","author":"Akizawa","year":"2000","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub4-BIB0003|cit3","first-page":"755A","article-title":"Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients - a randomized, open label, dose titration study of PB-94 versus caltan\u00ae tablet 500 (calcium carbonate) [abstract]","volume":"12","author":"Kinugasa","year":"2001","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/1744-9987.12068","article-title":"Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia","volume":"18","author":"Akizawa","year":"2014","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0005|cit5","first-page":"501a","article-title":"A phase III, sevelamer HCI-controlled study of bixalomer in chronic kidney disease patients on hemodialysis with hyperphosphatemia [abstract no: FR-PO1669]","volume":"22","author":"Akizawa","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1744-9987.12461","article-title":"Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial","volume":"20","author":"Akizawa","year":"2016","journal-title":"Therapeutic Apheresis and Dialysis"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0007|cit7","first-page":"B5","article-title":"Phase III study of ASP1585 ( bixalomer)- randomized, double-blind, placebo-controlled study in chronic kidney disease patients with hyperphosphatemia not on dialysis [abstract no: SA-PO1104]","volume":"25","author":"Akizawa","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3968\/j.ans.1715787020120501.1001","article-title":"The effect of coadministration of nicotinamide and calcium-based phosphate binder on hyperphosphatemia in patients undergoing hemodialysis","volume":"5","author":"Allam","year":"2012","journal-title":"Advances in Natural Science"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"A152","DOI":"10.1016\/j.jval.2012.03.821","article-title":"The effect of coadminstration of nicotinamide and calcium-based phosphate binder on hyperphophatemia in patients undergoing hemodialysis [abstract]","volume":"15","author":"Allam","year":"2012","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0010|cit10","first-page":"i253","article-title":"Lowdose nicotinamide as an adjunctive therapy to calcium carbonate for control of hyperphosphatemia in hemodialysis patients [abstract]","volume":"28","author":"ElSharkawy","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0011|cit11","first-page":"976","article-title":"Ca acetate versus Ca carbonate for the control of serum phosphate in haemodialysis patients [abstract]","volume":"8","author":"Almirall","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000168713","article-title":"Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients","volume":"14","author":"Almirall","year":"1994","journal-title":"American Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/j.ajkd.2019.01.029","article-title":"Effects of sevelamer carbonate in patients with CKD and proteinuria: the ANSWER randomized trial","volume":"74","author":"Ruggiero","year":"2019","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5301\/jn.5000011","article-title":"Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients","volume":"25","author":"Aramwit","year":"2012","journal-title":"Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0015|cit15","first-page":"212A","article-title":"Effectiveness and safety of extended-release nicotinic acid for the reduction of serum phosphorus level in maintenance hemodialysis patients [abstract no: TH-PO446]","volume":"21","author":"Supasyndh","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12882-021-02575-9","article-title":"Association of fibroblast growth factor 23 and alpha-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study","volume":"22","author":"Ito","year":"2021","journal-title":"BMC Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0017|cit17","first-page":"891","article-title":"A prospective study examining the contribution to renal anemia treatment of ferric citrate hydrate, an iron-based oral phosphate binder, in hemodialysis patients with hyperphosphatemia: ASTRIO study [abstract no: SA-PO818]","volume":"28","author":"Yokoyama","year":"2017","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"8877","DOI":"10.1038\/s41598-019-45335-4","article-title":"Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study","volume":"9","author":"Yokoyama","year":"2019","journal-title":"Scientific Reports"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0019|cit19","first-page":"161","article-title":"Effect of ferric citrate hydrate on FGF23 and serum a-Klotho in hemodialysis patients with hyperphosphatemia and controlled serum phosphate levels: ASTRIO study supplementary analysis [abstract no: TH-PO192]","volume":"29","author":"Yokoyama","year":"2018","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0020|cit20","first-page":"827","article-title":"Ferric citrate hydrate on anemia management in hyperphosphatemia hemodialysis patients with or without diabetes: ASTRIO study supplementary analysis [abstract]","volume":"30","author":"Yokoyama","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/ndt\/14.6.1475","article-title":"Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study","volume":"14","author":"Birck","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub4-BIB0022|cit22","first-page":"552A","article-title":"Calcium-ketoglutarate vs. calcium-acetate for treatment of hyperphosphatemia in patients on maintenance hemodialysis [abstract]","volume":"9","author":"Birck","year":"1998","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub4-BIB0024|cit24","first-page":"548a","article-title":"An open label, cross-over study of the new phosphate binder renagel in the management of hyperphosphatemia in ESRD patients [abstract]","volume":"8","author":"Bleyer","year":"1997","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0025|cit25","first-page":"iv294","article-title":"Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]","volume":"21","author":"Block","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1093\/ndt\/gft264","article-title":"Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial","volume":"28","author":"D'Marco","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0029|cit29","first-page":"735A","article-title":"Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA-PO818]","volume":"16","author":"Galassi","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/ndt\/gfl395","article-title":"Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders","volume":"21","author":"Galassi","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40620-016-0310-9","article-title":"Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial","volume":"29","author":"Ko","year":"2016","journal-title":"Journal of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0032|cit32","first-page":"53a","article-title":"Risk factors for mortality in patients new to dialysis [abstract no: F-FC080]","volume":"17","author":"Spiegel","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1492-7535.2004.01104.x","article-title":"Coronary and aortic calcifications in patients new to dialysis","volume":"8","author":"Spiegel","year":"2004","journal-title":"Hemodialysis International"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/ndt\/gfm424","article-title":"Factors associated with mortality in patients new to haemodialysis","volume":"22","author":"Spiegel","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1542-4758.2009.00387.x","article-title":"A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology","volume":"13","author":"Block","year":"2009","journal-title":"Hemodialysis International"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ndt\/gfaa010","article-title":"Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease","volume":"35","author":"Ginsberg","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.ajkd.2017.06.017","article-title":"Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD","volume":"71","author":"Jovanovich","year":"2018","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0039|cit39","first-page":"762A","article-title":"Deoxycholic acid (DCA), a metabolite of circulating bile acids and coronary vascular calcifications in chronic kidney disease (CKD) [abstract no: SA-PO598]","volume":"26","author":"Miyazaki","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1053\/j.jrn.2017.07.002","article-title":"Variation in sodium intake and intra-individual change in blood pressure in chronic kidney disease","volume":"28","author":"Pathak","year":"2018","journal-title":"Journal of Renal Nutrition"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0041|cit41","first-page":"792A","article-title":"A new equation to predict 24-hour urinary phosphorus [abstract no: SA-PO662]","volume":"23","author":"Robinson-Cohen","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.jrn.2014.02.001","article-title":"Estimation of 24-hour urine phosphate excretion from spot urine collection: development of a predictive equation","volume":"24","author":"Robinson-Cohen","year":"2014","journal-title":"Journal of Renal Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ckj\/sfu017","article-title":"Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4","volume":"7","author":"Weber","year":"2014","journal-title":"Clinical Kidney Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0044|cit44","first-page":"iii156","article-title":"Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract no: SP253]","volume":"29","author":"Block","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0045|cit45","first-page":"iii151","article-title":"A double-blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron-deficiency anemia and reduction of serum phosphate in patients with non-dialysis dependent chronic kidney disease [abstract no: SP238]","volume":"29","author":"Block","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1053\/j.ajkd.2015.02.037","article-title":"Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3-5 chronic kidney disease (CKD) [abstract]","volume":"65","author":"Block","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5","volume":"65","author":"Block","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"A118","DOI":"10.1053\/j.ajkd.2014.01.440","article-title":"ZerenexTM (ferric citrate) for the treatment of iron-deficiency anemia and reduction of serum phosphate in non-dialysis dependent CKD [abstract]","volume":"63","author":"Block","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"e0188712","DOI":"10.1371\/journal.pone.0188712","article-title":"Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease","volume":"12","author":"Chertow","year":"2017","journal-title":"PLOS One [Electronic Resource]"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"A35","DOI":"10.1053\/j.ajkd.2015.02.085","article-title":"Auryxia (ferric citrate), an oral iron-based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]","volume":"65","author":"Fishbane","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0051|cit51","first-page":"1637","article-title":"Randomized trial of the effects of ferric citrate in patients with advanced chronic kidney disease [abstract no: LB05]","volume":"33","author":"Block","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1681\/ASN.2018101016","article-title":"A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD","volume":"30","author":"Block","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0053|cit53","first-page":"482","article-title":"A randomized trial of ferric citrate in advanced CKD: safety [abstract no: FR-PO243]","volume":"29","author":"Block","year":"2018","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bone.2016.07.009","article-title":"The pitfall of treating low bone turnover: effects on cortical porosity","volume":"91","author":"Araujo","year":"2016","journal-title":"Bone"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/j.1523-1755.2005.00239.x","article-title":"Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors","volume":"67","author":"Barreto","year":"2005","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1053\/j.ajkd.2008.06.024","article-title":"Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study","volume":"52","author":"Barreto","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0057|cit57","first-page":"c273","article-title":"Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0058|cit58","first-page":"738A","article-title":"Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one-year follow-up [abstract no: SA-PO831]","volume":"16","author":"Barreto","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002769","article-title":"K\/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients","volume":"73","author":"Barreto","year":"2008","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0060|cit60","first-page":"c74","article-title":"Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate","volume":"117","author":"Cancela","year":"2011","journal-title":"Nephron"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0061|cit61","first-page":"694A","article-title":"Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU-PO723]","volume":"14","author":"Canziani","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0062|cit62","first-page":"532A","article-title":"Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA-PO863]","volume":"18","author":"Oliveira","year":"2007","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1542-4758.2009.00369.x","article-title":"Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients","volume":"13","author":"Peres","year":"2009","journal-title":"Hemodialysis International"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/ajkd.1998.v31.pm9469496","article-title":"Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis","volume":"31","author":"Bro","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2215\/CJN.02810707","article-title":"Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients","volume":"3","author":"Caglar","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/ndt\/gft203","article-title":"A comparison of calcium acetate\/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study","volume":"28","author":"Covic","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0068|cit68","first-page":"iii40","article-title":"Serum calcification propensity of HD patients is therapeutically improved by a calcium acetate\/ magnesium carbonate containing phosphate binder [abstract no: MO044]","volume":"29","author":"Pasch","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/ndt\/gfq292","article-title":"Evaluation of calcium acetate\/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability","volume":"25","author":"Francisco","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0070|cit70","first-page":"423","article-title":"Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients","volume":"60","author":"Caravaca","year":"1992","journal-title":"Nephron"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0071|cit71","first-page":"729","article-title":"Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients [abstract]","volume":"5","author":"Caravaca","year":"1990","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0072|cit72","first-page":"207A","article-title":"Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F-PO664]","volume":"14","author":"Nolan","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.acra.2007.08.011","article-title":"The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study","volume":"15","author":"Budoff","year":"2008","journal-title":"Academic Radiology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub4-BIB0075|cit75","first-page":"866A","article-title":"Cardiovascular calcification (CVC) in hemodialysis (HD) patients: study design and preliminary mineral data of the calcium acetate sevelamer evaluation-2 (CARE-2) study [abstract no: PUB386]","volume":"16","author":"Qunibi","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub4-BIB0076|cit76","first-page":"vi148","article-title":"Progression of coronary artery calcification (CAC) in hemodialysis patients (HDP) despite excellent control of LDL cholesterol: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study [abstract no: FP386]","volume":"22","author":"Qunibi","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0077|cit77","first-page":"286A","article-title":"Coronary artery calcification (CAC) in hemodialysis patients (HDP): preliminary results from the calcium acetate renagel evaluation-2 (CARE-2) study [abstract no: TH-PO845]","volume":"17","author":"Qunibi","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/ndt\/gfn520","article-title":"The CARE-2 study results: setting the record straight","volume":"23","author":"Qunibi","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0080|cit80","unstructured":"Qunibi WY Moustafa M Kessler P Bortey E Muenz LR Budoff M Coronary artery calcification (CAC) progression in hemodialysis patients (HDP) treated with atorvastatin: the calcium acetate renagel evaluation-2 (CARE-2) study [abstract no: S-PO-0376] 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 150"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub4-BIB0081|cit81","first-page":"10A","article-title":"Progression of aorta calcification (AoC) in hemodialysis patients (HDP) treated with calcium acetate (CaA) or sevelamer (SV) with comparable lipid control: the calcium acetate renegal evaluation-2 (CARE-2) study [abstract no: TH-FC043]","volume":"19","author":"Qunibi","year":"2008","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s10157-016-1362-9","article-title":"Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients","volume":"21","author":"Chang","year":"2017","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0083|cit83","first-page":"647A","article-title":"SBR759 is well-tolerated with good gastrointestinal tolerability profile compared to sevelamer hydrochloride [abstract no: SA-PO2348]","volume":"21","author":"Akiba","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1440-1797.2011.01509.x","article-title":"Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride","volume":"16","author":"Chen","year":"2011","journal-title":"Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0085|cit85","first-page":"51","article-title":"SBR759, a novel phosphate binder, effectively controls hyperphosphatemia in Asian patients on hemodialysis versus sevelamer [abstract no: FP08-08]","volume":"15","author":"Chen","year":"2010","journal-title":"Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0086|cit86","first-page":"647A","article-title":"SBR759 is more effective than sevelamer hydrochloride in sustaining serum phosphate reduction in hemodialysis patients [abstract no: SA-PO2347]","volume":"21","author":"Chen","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0087|cit87","first-page":"iii238","article-title":"SBR759, a novel phosphate binder, is superior to sevelamer HCL in controlling hyperphosphatemia in Asian patients on hemodialysis [abstract no: SA582]","volume":"3","author":"Chen","year":"2010","journal-title":"NDT Plus"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/ndt\/gft232","article-title":"Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study","volume":"29","author":"Chen","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0089|cit89","first-page":"392A","article-title":"A randomized, double-blind, placebo-controlled,dose-titration study of sevelamer carbonate in hemodialysis patients [abstract no: FR-PO1211]","volume":"22","author":"Chen","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000527833","article-title":"Efficacy and safety of sevelamer carbonate in Chinese nondialysis chronic kidney disease patients with hyperphosphatemia: a randomized, double-blind, parallel-group study","volume":"9","author":"Chen","year":"2023","journal-title":"Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0091|cit91","first-page":"iii1202","article-title":"Efficacy and safety of sevelamer carbonate in non-dialysis hyperphosphatemia patients: a randomized, double blind, parallel group study for the treatment of hyperphosphatemia in patients with chronic kidney disease not on dialysis in China [abstract no: P0880]","volume":"35","author":"Yu","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0092|cit92","first-page":"924A","article-title":"The effect of oral niacinamide on serum phosphorus levels in hemodialysis patients [abstract no: PUB430]","volume":"18","author":"Cheng","year":"2007","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1755-6686.2013.12009.x","article-title":"Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis","volume":"39","author":"Chennasamudram","year":"2013","journal-title":"Journal of Renal Care"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0095|cit95","first-page":"842A","article-title":"Pleiotropic effects sevelamer in peritoneal dialysis patients with type II diabetes mellitus [abstract no: SA-PO876]","volume":"23","author":"Chennasamudram","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0096|cit96","first-page":"18","article-title":"A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients","volume":"51","author":"Chertow","year":"1999","journal-title":"Clinical Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/ndt\/gfh894","article-title":"Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density","volume":"20","author":"Asmus","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0098|cit98","first-page":"32","article-title":"Sevelamer is more effective than calcium in the management of mineral metabolism and arterial calcification [abstract no: O106]","volume":"17","author":"Bommer","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0099|cit99","first-page":"A122","article-title":"Lipid lowering effect of renagel, a novel phosphate binder [abstract]","volume":"16","author":"Bommer","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5414\/CNP62104","article-title":"Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification","volume":"62","author":"Braun","year":"2004","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney International"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006023.pub4-BIB0102|cit102","first-page":"433A","article-title":"The \"tip of the iceberg\" matters: exposure to high normal serum calcium concentration leads to accelerated coronary artery and aortic calcification in hemodialysis patients treated with calcium-based phosphate binders [abstract]","volume":"13","author":"Chertow","year":"2002","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub4-BIB0103|cit103","first-page":"195","article-title":"Sevelamer is more effective at controlling disorders of mineral metabolism than calcium-based phosphate binders in hemodialysis patients [abstract]","volume":"12","author":"Chertow","year":"2001","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006023.pub4-BIB0104|cit104","first-page":"386A","article-title":"In hemodialysis patients, sevelamer (renagel) attenuates coronary artery and aortic calcification and reduces LDL-C, APO-B, and HS-CRP compared with calcium acetate (PHOSLO) [abstract no: SA-PO603]","volume":"13","author":"Chertow","year":"2002","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/ndt\/gfh125","article-title":"Determinants of progressive vascular calcification in haemodialysis patients","volume":"19","author":"Chertow","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000072822","article-title":"The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients","volume":"23","author":"Chertow","year":"2003","journal-title":"American Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ahj.2004.07.023","article-title":"Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients","volume":"149","author":"Ferramosca","year":"2005","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.20781","article-title":"Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial","volume":"52","author":"Garg","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0109|cit109","first-page":"681","article-title":"Thoracic vertebral bone density increases with renagel and decreases with calcium-based phosphate binder therapy - a two year study [abstract no: W423]","volume":"18","author":"James","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0110|cit110","first-page":"134","article-title":"Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer","volume":"13","author":"Raggi","year":"2004","journal-title":"Journal of Heart Valve Disease"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0111|cit111","unstructured":"Raggi P Burke S Chasen-Taber S Chertow G Holzer H Bommer J Sevelamer preserves trabecular bone mineral density [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 103 4"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0112|cit112","first-page":"502A","article-title":"Sevelamer preserves and calcium reduces trabecular bone mineral density [abstract no: SA-PO924]","volume":"14","author":"Raggi","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub4-BIB0113|cit113","first-page":"239A","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium-based phosphate binders [abstract]","volume":"12","author":"Raggi","year":"2001","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/JBMR.041221","article-title":"Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis","volume":"20","author":"Raggi","year":"2005","journal-title":"Journal of Bone & Mineral Research"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0115|cit115","first-page":"413","article-title":"Magnetic resonance measurements of intra-renal oxygenation and fibrosis and change in kidney function: COMBINE trial [abstract no: TH-PO1125]","volume":"29","author":"Isakova","year":"2018","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0116|cit116","first-page":"164","article-title":"Effects of lanthanum carbonate on mineral metabolism in normophosphatemic patients with CKD: secondary analysis of the COMBINE trial [abstract no: TH-PO200]","volume":"29","author":"Isakova","year":"2018","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1681\/ASN.2018101058","article-title":"Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE trial","volume":"30","author":"Ix","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0118|cit118","first-page":"911A","article-title":"A new approach to phosphate and FGF23 lowering: design of the COMBINE trial [abstract no: PUB111]","volume":"26","author":"Ix","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0119|cit119","first-page":"475","article-title":"Determinants of C-terminal vs. intact FGF-23 in CKD: the COMBINE trial [abstract no: FR-PO161]","volume":"30","author":"Ix","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0120|cit120","first-page":"1634","article-title":"Effects of nicotinamide and lanthanum carbonate on serum phosphate and FGF23 concentrations in chronic kidney disease: primary results of the COMBINE trial [abstract no: FP803]","volume":"33","author":"Isakova","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1681\/ASN.20203110S1163c","article-title":"Effect of lanthanum carbonate on blood pressure in CKD: The COMBINE trial [abstract]","volume":"31","author":"Jamshidian","year":"2020","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1053\/j.ajkd.2020.12.012","article-title":"Effect of lanthanum carbonate on blood pressure in CKD","volume":"78","author":"Jamshidian","year":"2021","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2215\/CJN.13201019","article-title":"Kidney functional magnetic resonance imaging and change in eGFR in individuals with CKD in eGFR in individuals with CKD","volume":"15","author":"Srivastava","year":"2020","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2012070719","article-title":"Cardiovascular effects of sevelamer in stage 3 CKD","volume":"24","author":"Chue","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1745-6215-12-30","article-title":"Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial","volume":"12","author":"Chue","year":"2011","journal-title":"Trials"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients","volume":"85","author":"D'Haese","year":"2003","journal-title":"Kidney International. Supplement"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0127|cit127","first-page":"A28","article-title":"Multi-centre study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients [abstract no: PS1-15]","volume":"8","author":"D'Haese","year":"2003","journal-title":"Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0128|cit128","first-page":"682","article-title":"Comparative effects of lanthanum carbonate (fosrenol) and calcium carbonate on renal bone disease in dialysis patients: results from a large, long-term clinical trial [abstract]","volume":"18","author":"De Broe","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0129|cit129","unstructured":"Freemont A Jones C The effects of the phosphate binders lanthanum carbonate and calcium carbonate on bone: a comparative study in patients with chronic kidney disease [abstract no:SP270] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 106"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0130|cit130","first-page":"A23","article-title":"The effects of lanthanum carbonate and calcium carbonate on bone in patients with chronic kidney disease [abstract no: 33]","volume":"43","author":"Freemont","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0131|cit131","first-page":"428","article-title":"The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease","volume":"64","author":"Freemont","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5414\/CNP63138","article-title":"Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate","volume":"63","author":"Freemont","year":"2005","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0133|cit133","unstructured":"Request for information concerning study methods and baseline characteristics Email to: RS Wilson, PICA Consultants Ltd 2011"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0134|cit134","first-page":"764A","article-title":"One-year, randomized, open-label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol\u00ae) and calcium carbonate in dialysis patients [abstract no: SU-PO1041]","volume":"14","author":"Torres","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0135|cit135","first-page":"146","article-title":"Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]","volume":"31","author":"Webster","year":"2004","journal-title":"Nephrology Nursing Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub4-BIB0136|cit136","first-page":"ii496","article-title":"Lower serum phosphorus can be attained by increasing the dose of lanthanum carbonate [abstract]","volume":"27","author":"Wilson","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0137|cit137","first-page":"882a","article-title":"Increasing the dose of lanthanum carbonate results in better serum phosphorus control [abstract no: PUB164]","volume":"22","author":"Wilson","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0138|cit138","first-page":"287A","article-title":"DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH-PO846]","volume":"17","author":"St Peter","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2215\/CJN.04100609","article-title":"Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data","volume":"4","author":"St Peter","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.ajkd.2007.12.002","article-title":"A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data","volume":"51","author":"St Peter","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1542-4758.2008.00312.x","article-title":"Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results","volume":"12","author":"St Peter","year":"2008","journal-title":"Hemodialysis International"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0142|cit142","first-page":"287A","article-title":"DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH-PO847]","volume":"17","author":"StPeter","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0143|cit143","first-page":"iv145","article-title":"A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients - the DCOR trial [abstract no: SP392]","volume":"21","author":"Suki","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0144|cit144","first-page":"281A","article-title":"The DCOR trial - a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH-PO745]","volume":"16","author":"Suki","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.jrn.2007.10.019","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial","volume":"18","author":"Suki","year":"2008","journal-title":"Journal of Renal Nutrition"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0147|cit147","unstructured":"Delmez JA Kelber J Norwood KY Giles KS Slatopolsky E The clinical evaluation of magnesium carbonate (MgCo3) as a phosphorous (P) binder in the suppression of secondary hyperparathyroidism [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 416"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ki.1996.22","article-title":"Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study","volume":"49","author":"Delmez","year":"1996","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"A36","DOI":"10.1053\/j.ajkd.2007.02.052","article-title":"A randomized, double-blind cross-over design study of sevelamer hydrochloride (SH, Renegel\u00ae) and sevelamer carbonate (SC) in chronic kidney disease patients on hemodialysis [abstract no: 48]","volume":"49","author":"Delmez","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub4-BIB0150|cit150","first-page":"vi361","article-title":"Results of a randomized, double-blind, cross-over design study of sevelamer hydrochloride (Renagel\u00ae) and sevelamer carbonate in chronic kidney disease patients on hemodialysis [abstract no: SaP377]","volume":"22","author":"Delmez","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5414\/CNP68386","article-title":"A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis","volume":"68","author":"Delmez","year":"2007","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1093\/joneph\/19.S9.S108","article-title":"Sevelamer worsens metabolic acidosis in hemodialysis patients","volume":"19 Suppl 9","author":"De Santo","year":"2006","journal-title":"Journal of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0153|cit153","first-page":"680","article-title":"Effective reduction of serum phosphate by a calcium and magnesium containing phosphate binder without induction of hypermagnesemia [abstract no: W422]","volume":"18","author":"Deuber","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5414\/NHP33403","article-title":"Combined use of calcium acetate and magnesium carbonate as phosphate binder","volume":"33","author":"Deuber","year":"2004","journal-title":"Nieren und Hochdruckkrankheiten"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"714205","DOI":"10.3389\/fmed.2021.714205","article-title":"The influence of sevelamer hydrochloride and calcium carbonate on markers of inflammation and oxidative stress in hemodialysis at six months of follow-up","volume":"8","author":"Diaz-De la Cruz","year":"2021","journal-title":"Frontiers in Medicine"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0156|cit156","first-page":"1051","article-title":"Rationale, design, and characteristics of EPISODE trial [abstract no: PUB088]","volume":"29","author":"Isaka","year":"2018","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s10157-018-1547-5","article-title":"Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE)","volume":"22","author":"Isaka","year":"2018","journal-title":"Clinical and Experimental Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0158|cit158","first-page":"49","article-title":"A randomized trial of optimal phosphate range for coronary artery calcification in dialysis patients [abstract no: FR-OR031]","volume":"30","author":"Isaka","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1681\/ASN.2020050598","article-title":"Optimal phosphate control related to coronary artery calcification in dialysis patients","volume":"32","author":"Isaka","year":"2021","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ndt\/gfn488","article-title":"Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis","volume":"24","author":"Evenepoel","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0161|cit161","first-page":"iv496","article-title":"Effects of sevelamer hydrochloride (Renagel\u00ae) and calcium acetate on controlling serum phosphorus in peritoneal dialysis patients [abstract no: MP580]","volume":"21","author":"Evenepoel","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0162|cit162","first-page":"272A","article-title":"Comparative effects of sevelamer hydrochloride (Renagel\u00ae) and calcium acetate on markers of mineral metabolism in peritoneal dialysis patients [abstract no: TH-PO778]","volume":"17","author":"Evenepoel","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3747\/pdi.2013.00129","article-title":"MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial","volume":"35","author":"Evsanaa","year":"2015","journal-title":"Peritoneal Dialysis International"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2006101089","article-title":"Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients","volume":"19","author":"Ferreira","year":"2008","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0165|cit165","unstructured":"Fishbane S Delmez J Suki W Hariachar S Moe S Heaton J Sevelamer carbonate powder dosed once per day and sevelamer hydrochloride tablets dosed three times per day: a randomized, parallel, open-label study in chronic kidney disease patients on hemodialysis [abstract no: M621] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub4-BIB0166|cit166","first-page":"936A","article-title":"A randomized, parallel, open-label study to compare once per day sevelamer carbonate powder dosing with three times per day sevelamer hydrochloride tablet dosing in chronic kidney disease patients on hemodialysis [abstract no: PUB556]","volume":"19","author":"Fishbane","year":"2008","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.ajkd.2009.10.051","article-title":"A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis","volume":"55","author":"Fishbane","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0168|cit168","first-page":"303A","article-title":"Effects of ferric citrate on parameters of mineral and bone metabolism in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) treated for iron deficiency anemia (IDA) [abstract no: TH-PO903]","volume":"27","author":"Block","year":"2016","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/ndt\/gfy318","article-title":"Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses","volume":"34","author":"Block","year":"2019","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0170|cit170","first-page":"232","article-title":"Ferric citrate lowered serum phosphate only when elevated in patients with nondialysis-dependent (NDD) CKD and iron deficiency anemia (IDA) [abstract no: TH-PO514]","volume":"28","author":"Block","year":"2017","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0171|cit171","first-page":"11","article-title":"Ferric citrate reduced FGF23 in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and iron deficiency anemia (IDA) irrespective of the change in serum phosphate (P) [Abstract no: TH-OR038]","volume":"28","author":"Block","year":"2017","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0172|cit172","first-page":"303A","article-title":"Hemoglobin response to ferric citrate (FC) in subjects with non-dialysis dependent (NDD) chronic kidney disease (CKD) and iron deficiency anemia (IDA): data from a phase 3 clinical trial [abstract no: TH-PO902]","volume":"27","author":"Chertow","year":"2016","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0174|cit174","first-page":"303A","article-title":"Effects of ferric citrate (FC) in adults with non-dialysis-dependent chronic kidney disease and iron-deficiency anemia (IDA): ph 3 clinical trial [abstract no: TH-PO901]","volume":"27","author":"Fishbane","year":"2016","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.amjcard.2018.04.062","article-title":"Usefulness of oral ferric citrate in patients with iron-deficiency anemia and chronic kidney disease with or without heart failure","volume":"122","author":"McCullough","year":"2018","journal-title":"American Journal of Cardiology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0176|cit176","first-page":"303A","article-title":"Preditors of hemoglobin response to ferric citrate in patients with non-dialysis dependent chronic kidney disease and iron deficiency anemia [abstract no: TH-PO904]","volume":"27","author":"Pergola","year":"2016","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"E154","DOI":"10.1002\/ajh.25088","article-title":"Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia","volume":"93","author":"Pergola","year":"2018","journal-title":"American Journal of Hematology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0178|cit178","first-page":"iii153","article-title":"Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract no: SP245]","volume":"29","author":"Covic","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0179|cit179","first-page":"iii152","article-title":"Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract no: SP241]","volume":"29","author":"Covic","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"iii202","DOI":"10.1093\/ndt\/gfv176.21","article-title":"FP397 Post hoc analysis of iron indices in dialysis patients with lower vs higher baseline ferritin in a phase 3 study of sucroferric oxyhydroxide [abstract]","volume":"30","author":"Covic","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"iii197","DOI":"10.1093\/ndt\/gfv176.07","article-title":"Post hoc analysis of IV iron and ESA use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]","volume":"30","author":"Covic","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/ndt\/gfw242","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","volume":"32","author":"Covic","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1159\/000507258","article-title":"Characteristics of patients who achieve serum phosphorus control on sucroferric oxyhydroxide or sevelamer carbonate: a post hoc analysis of a phase 3 study","volume":"144","author":"Covic","year":"2020","journal-title":"Nephron"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0184|cit184","first-page":"iii157","article-title":"PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract no: SP257]","volume":"29","author":"Floege","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0185|cit185","unstructured":"Floege J Covic A Ketteler M Mann J Rastogi A Spinowitz B Efficacy and safety of novel iron-based phosphate binder PA21 in peritoneal- and haemodialysis dependent CKD patients [abstract no: P43] EuroPD 2013. 11th European Peritoneal Dialysis Meeting; 2013 Oct 11-14; Maastricht, Netherlands 2013"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0186|cit186","first-page":"i155","article-title":"Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron-based phosphate binder [abstract no: SP246]","volume":"28","author":"Floege","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfw460","article-title":"One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis","volume":"32","author":"Floege","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0190|cit190","first-page":"6B","article-title":"Efficacy and safety of PA21 in hyperphosphatemic CKD patients on dialysis [abstract no: SA-PO1103]","volume":"23","author":"Floege","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0191|cit191","first-page":"iii152","article-title":"Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract no: SP42]","volume":"29","author":"Floege","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"i461","DOI":"10.1093\/ndt\/gfw190.22","article-title":"Sucroferric oxyhydroxide does not impact the iPTH-lowering effects of oral VDRAS or cinacalcet: a post hoc analysis of a phase 3 study [abstract no: MP365]","volume":"31","author":"Floege","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"i466","DOI":"10.1093\/ndt\/gfw190.38","article-title":"Characteristics of responders and non-responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract no: MP381]","volume":"31","author":"Floege","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0194|cit194","first-page":"222A","article-title":"Characteristics of responders and non-responders to phosphate binder therapy: a post hoc analysis of a phase 3 study [abstract no: PO-TH564]","volume":"27","author":"Floege","year":"2016","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0195|cit195","first-page":"i155","article-title":"PA21, a novel iron-based phosphate binder, showed no interaction with fat-soluble vitamins in a phase 3 study [abstract no: SP247]","volume":"28","author":"Ketteler","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0196|cit196","first-page":"222A","article-title":"Effect of non-calcium phosphate binders on CKD-MBD indicies in dialysis patients: a post hoc analysis of a phase 3 study [abstract no: TH-PO565}","volume":"27","author":"Ketteler","year":"2016","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/ndt\/gfy127","article-title":"Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients","volume":"34","author":"Ketteler","year":"2019","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"A81","DOI":"10.1053\/j.ajkd.2013.02.266","article-title":"PA21 - a novel iron-based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]","volume":"61","author":"Rastogi","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1053\/j.ajkd.2014.01.318","article-title":"No clinically relevant changes in vitamin D concentrations with PA21, a novel iron-based phosphate binder, over 52 weeks [abstract]","volume":"63","author":"Rastogi","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0200|cit200","first-page":"568A","article-title":"Sucroferric oxyhydroxide does not affect oral vitamin D agonists: post hoc analysis of phase 3 data [abstract no: FR-PO860]","volume":"25","author":"Sprague","year":"2014","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"A105","DOI":"10.1053\/j.ajkd.2014.01.364","article-title":"Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]","volume":"63","author":"Sprague","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"A80","DOI":"10.1053\/j.ajkd.2015.02.264","article-title":"Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]","volume":"65","author":"Sprague","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0203|cit203","first-page":"923a","article-title":"Concomitant intravenous iron use drives change in iron indices across geographical regions in a sucroferric oxyhydroxide study [abstract no: PUB129]","volume":"25","author":"Sprague","year":"2014","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0204|cit204","first-page":"260a","article-title":"Post hoc analysis of iron indices in dialysis patients with lower versus higher baseline ferritin in a sucroferric oxyhydroxide study [abstract no: TH-PO670]","volume":"25","author":"Sprague","year":"2014","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000447600","article-title":"Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients","volume":"44","author":"Sprague","year":"2016","journal-title":"American Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0206|cit206","first-page":"7A","article-title":"Efficacy of PA21, a novel iron-based phosphate binder, maintained to 52 weeks in dialysis patients with hyperphosphatemia [abstract no: TH-OR027]","volume":"24","author":"Sprague","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/hdi.12663","article-title":"Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients","volume":"22","author":"Sprague","year":"2018","journal-title":"Hemodialysis International"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0208|cit208","first-page":"A104","article-title":"1-year efficacy and safety of sucroferric oxyhydroxide in a sub-population of African American dialysis patients [abstract]","volume":"67","author":"Sprague","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0209|cit209","first-page":"A104","article-title":"FGF-23 and CKD-MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]","volume":"67","author":"Sprague","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0210|cit210","first-page":"235A","article-title":"CKD-MBD indices after 52 weeks of sucroferric oxyhdroxide, an iron-based phosphate binder in African American dialysis patients [abstract no: TH-PO642]","volume":"26","author":"Sprague","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0211|cit211","first-page":"236A","article-title":"Concomitant IV iron use drives changes in iron indices in African American dialysis patients over 52 weeks of sucroferric oxyhydroxide treatment [abstract no: TH-PO643]","volume":"26","author":"Sprague","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0212|cit212","first-page":"664A","article-title":"Efficacy, safety and pill burden of sucroferric oxyhydroxide, an iron-based phosphate binder, over 52 weeks in African American dialysis patients [abstract no: SA-PO174]","volume":"26","author":"Sprague","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1-3","key":"10.1002\/14651858.CD006023.pub4-BIB0213|cit213","first-page":"212","article-title":"Evaluating the management of hyperphosphatemia with PA21 in dialysis patients-rationale and design of an open-label, randomised, active-controlled phase 3 study [abstract]","volume":"33","author":"Tumlin","year":"2012","journal-title":"Blood Purification"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0214|cit214","first-page":"861A","article-title":"Rationale and design of an open-label, randomised, active-controlled phase 3 study evaluating the management of hyperphosphatemia with PA21 in dialysis patients [abstract no: PUB075]","volume":"22","author":"Tumlin","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0215|cit215","first-page":"296","article-title":"Calcium acetate. A good alternative to calcium carbonate for treating hyperphosphoremia in chronic hemodialysis patients with high risk of hypercalcemia","volume":"18","author":"Foraster","year":"1998","journal-title":"Nefrologia"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"E279","DOI":"10.3390\/toxins11050279","article-title":"The effect of sevelamer on serum levels of gut-derived uremic toxins: results from in vitro experiments and a multicenter, double-blind, placebo-controlled, randomized clinical trial","volume":"11","author":"Bennis","year":"2019","journal-title":"Toxins"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"iii199","DOI":"10.1093\/ndt\/gfx145.SP273","article-title":"The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]","volume":"32","author":"Liabeuf","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"iii207","DOI":"10.1093\/ndt\/gfv177.08","article-title":"FP409 Sevelamer carbonate reduces phosphaturia but has no effect on serumc-terminal fibroblast growth factor 23 levels in stage 3b\/4 CKD patients : the results of a French, multicenter, double-blind, placebo-control, randomized clinical trial [abstract]","volume":"30","author":"Liabeuf","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub4-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2215\/CJN.03030317","article-title":"Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD","volume":"12","author":"Liabeuf","year":"2017","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"iii645","DOI":"10.1093\/ndt\/gfx177.MP586","article-title":"MP586 Effect of lanthanum carbonate on cardiac abnormalities in patients new to hemodialysis [abstract]","volume":"32","author":"Fujii","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0221|cit221","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00223-017-0347-3","article-title":"Effects of lanthanum carbonate on coronary artery calcification and cardiac abnormalities after initiating hemodialysis","volume":"102","author":"Fujii","year":"2018","journal-title":"Calcified Tissue International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"i252","DOI":"10.1093\/ndt\/gfw172.17","article-title":"Effect of lanthanum carbonate on coronary artery calcification during the early period after the initiation of haemodialysis [abstract no: SP477]","volume":"31","author":"Fujii","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0223|cit223","first-page":"908","article-title":"The effects of lanthanum carbonate on bone metabolic markers and bone mineral density in incident hemodialysis patients [abstract no: SA-PO667]","volume":"29","author":"Goto","year":"2018","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00774-019-01018-8","article-title":"Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients","volume":"37","author":"Goto","year":"2019","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12872-020-01343-1","article-title":"Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis","volume":"20","author":"Watanabe","year":"2020","journal-title":"BMC Cardiovascular Disorders"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"i533","DOI":"10.1093\/ndt\/gfy104.SP548","article-title":"SP548 Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of valvular calcification after initiation of maintenance hemodialysis [abstract]","volume":"33","author":"Watanabe","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"iii244","DOI":"10.1093\/ndt\/gfx147.SP387","article-title":"Comparison of the suppressive effects on fibroblast growth factor 23 between ferric citrate and lanthanum carbonate [abstract]","volume":"32","author":"Fujimori","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0228|cit228","first-page":"746A","article-title":"Comparison of sevelamer HCL and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial - Calcium Carbonate Sevelamer Evaluation (CaCSE) study [abstract no: SA-PO867]","volume":"16","author":"Gallieni","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0229|cit229","unstructured":"Greenberg S Shapiro W Poruch JG Calcium acetate (CaA) vs calcium carbonate (CaCo) as a phosphorus (P) binder (B) in CAPD patients (pts) [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 472"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0230|cit230","unstructured":"Greenberg S Shapiro W Poruch JG Calcium acetate (aa) vs calcium carbonate (CaCo) as a phosphorus (P) binder (B) in CAPD patients (pts) [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 472"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0231|cit231","first-page":"492","article-title":"Calcium acetate (CAA) vs calcium carbonate (CaCo) as a phosphorus (P) binder (B) in CAPD patients (pts) [abstract]","volume":"5","author":"Greenberg","year":"1994","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1523-1755.63.s85.17.x","article-title":"Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate","volume":"85","author":"Hervas","year":"2003","journal-title":"Kidney International. Supplement"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0233|cit233","first-page":"141","article-title":"Efficacy and safety of lanthanum carbonate, the novel phosphate binder, in Chinese patients with chronic kidney disease [abstract]","volume":"31","author":"Gill","year":"2004","journal-title":"Nephrology Nursing Journal"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0234|cit234","first-page":"684","article-title":"Safety and tolerability of lanthanum carbonate in haemodialysis patients: a 12-month study [abstract no: W431]","volume":"18","author":"Hutchison","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0235|cit235","first-page":"205A","article-title":"Lanthanum carbonate versus calcium carbonate: effect on parathyroid hormone (PTH) levels [abstract no: F-PO656]","volume":"14","author":"Hutchison","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0236|cit236","first-page":"764A","article-title":"Maintained safety, tolerability and efficacy of lanthanum carbonate (Fosrenal\u00ae) during long-term therapy in hemodialysis patients [Abstract no: SU-PO1039]","volume":"14","author":"Hutchison","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0237|cit237","unstructured":"Hutchison A Webster I Safety and efficacy data for lanthanum carbonate: a summary from three studies [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 107"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub4-BIB0238|cit238","first-page":"v92","article-title":"Analysis of haematology data from over 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate [abstract no: SP219]","volume":"20","author":"Hutchison","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0239|cit239","first-page":"A297","article-title":"No adverse effects of haematological parameters during lanthanum carbonate treatment in over 2000 patients [abstract no: W-PO40068]","volume":"10","author":"Hutchison","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0240|cit240","first-page":"A298","article-title":"No evidence of hepatoxicity with lanthanum carbonate - clinical trial data from 2000 dialysis patients [abstract no: W-PO40069]","volume":"10","author":"Hutchison","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub4-BIB0241|cit241","first-page":"v5","article-title":"Long-term safety, efficacy and tolerability of lanthanum carbonate: results from a 3.5-year study [abstract no: SO07]","volume":"20","author":"Hutchison","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0242|cit242","first-page":"A297","article-title":"Long-term safety, efficacy, and tolerability of lanthanum carbonate: results from a 3.5-year study [abstract no: W-PO40065]","volume":"10","author":"Hutchison","year":"2005","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0243|cit243","unstructured":"Hutchison AJ Gill M A demographic analysis of lanthanum carbonate phase II and III studies [abstract no: 271] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 106 7"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0244|cit244","first-page":"c8","article-title":"Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate","volume":"100","author":"Hutchison","year":"2005","journal-title":"Nephron"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0245|cit245","first-page":"c61","article-title":"Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study","volume":"102","author":"Hutchison","year":"2006","journal-title":"Nephron"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0246|cit246","first-page":"A29","article-title":"Lanthanum carbonate (FosrenolTM), a novel, nonaluminum, noncalcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract no: PS1-22]","volume":"8","author":"Hutchison","year":"2003","journal-title":"Nephrology"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006023.pub4-BIB0247|cit247","first-page":"385","article-title":"The novel, non-aluminium, non-calcium phosphate binder, fosrenol, is an effective treatment for hyperphosphataemia and has a good safety profile [abstract no: SA-PO599]","volume":"13","author":"Hutchison","year":"2002","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0248|cit248","first-page":"149","article-title":"Lanthanum carbonate, a novel, non-aluminum, non-calcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract]","volume":"30","author":"Speake","year":"2003","journal-title":"Nephrology Nursing Journal"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0249|cit249","first-page":"143","article-title":"Long-term safety, tolerability, and efficacy of lanthanum carbonate therapy [abstract]","volume":"31","author":"Speake","year":"2004","journal-title":"Nephrology Nursing Journal"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0250|cit250","unstructured":"Webster I Gill M Lanthanum carbonate, a new phosphate binder, is well tolerated over a 3 year period in dialysis patients [abstract no: SP267] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 105"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0251|cit251","first-page":"146","article-title":"Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]","volume":"31","author":"Webster","year":"2004","journal-title":"Nephrology Nursing Journal"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0252|cit252","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1159\/000540227","article-title":"A randomized trial of the impact of ferric citrate on erythropoietin and intravenous iron use in patients receiving dialysis","volume":"55","author":"Block","year":"2024","journal-title":"American Journal of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0253|cit253","doi-asserted-by":"publisher","first-page":"e024382","DOI":"10.1136\/bmjopen-2018-024382","article-title":"Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study","volume":"9","author":"Lioufas","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0254|cit254","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000505717","article-title":"Aortic calcification and arterial stiffness burden in a chronic kidney disease cohort with high cardiovascular risk: baseline characteristics of the impact of phosphate reduction on vascular end-points in chronic kidney disease trial","volume":"51","author":"Lioufas","year":"2020","journal-title":"American Journal of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/ndt\/gfac043","article-title":"Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial","volume":"38","author":"Tiong","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0256|cit256","unstructured":"Toussaint N Pedagogos E IMpact of phosphate Reduction On Vascular End-points in CKD (IMPROVE-CKD): a randomized, placebo-controlled trial [abstract no: TH-PO1190] American Society of Nephrology, Kidney Week 2019; 2019 Nov 7; Washington DC, USA 2019 https:\/\/www.asn-online.org\/education\/kidneyweek\/2019\/program-abstract.aspx?controlId=3275630"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0257|cit257","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1681\/ASN.2020040411","article-title":"A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD)","volume":"31","author":"Toussaint","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40277-015-0052-4","article-title":"Cost-effectiveness of sevelamer versus calcium carbonate in non-dialysis dependent chronic kidney disease patients in Spain","volume":"13","author":"Del Pino","year":"2016","journal-title":"Pharmacoeconomics - Spanish Research Articles"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub4-BIB0259|cit259","first-page":"ii127","article-title":"Effect of phosphate binder therapy on mortality in pre-dialysis patients [abstract]","volume":"27","author":"Di Iorio","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: a randomized study","volume":"7","author":"Di Iorio","year":"2012","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000365746","article-title":"Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in Italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study","volume":"37","author":"Ruggeri","year":"2014","journal-title":"Blood Purification"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40620-014-0071-2","article-title":"Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease","volume":"28","author":"Russo","year":"2015","journal-title":"Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3111\/13696998.2013.792267","article-title":"Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom","volume":"16","author":"Thompson","year":"2013","journal-title":"Journal of Medical Economics"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0264|cit264","first-page":"8b","article-title":"Sevelamer is cost-effective versus calcium carbonate for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the UK [abstract no: SA-PO1111]","volume":"23","author":"Thompson","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5414\/CN108827","article-title":"Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study","volume":"86","author":"Bellasi","year":"2016","journal-title":"Clinical Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"iii588","DOI":"10.1093\/ndt\/gfv199.01","article-title":"Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract]","volume":"30","author":"Bellasi","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0267|cit267","first-page":"242A","article-title":"Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract no: TH-PO590]","volume":"25","author":"Bellasi","year":"2014","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","article-title":"Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial","volume":"62","author":"Di Iorio","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2013.09.005","article-title":"In reply to 'The change history of the INDEPENDENT Study in the ClinicalTrials.gov database'","volume":"63","author":"Di Iorio","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/joneph\/22.6.694","article-title":"Vascular calcification and QT interval in incident hemodialysis patients","volume":"22","author":"Di Iorio","year":"2009","journal-title":"Journal of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub4-BIB0271|cit271","first-page":"ii54","article-title":"Sevelamer attenuates CV mortality in incident hemodialysis patients: open label, randomized clinical trial of efficacy and safety (INDEPENDENT study) [abstract]","volume":"27","author":"Molony","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2013.08.022","article-title":"The change history of the INDEPENDENT Study in the ClinicalTrials.gov database","volume":"63","author":"Obi","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"717 [Erratum in","DOI":"10.1007\/s40620-014-0128-2","article-title":"Erratum to: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study","volume":"27","author":"Ruggeri","year":"2014","journal-title":"Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40620-014-0122-8","article-title":"Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study","volume":"28","author":"Ruggeri","year":"2015","journal-title":"Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0275|cit275","first-page":"9b","article-title":"Sevelamer dominates calcium carbonate in a patient-level cost-effectiveness analysis of the randomized, open-label, INDEPENDENT-HD study [abstract no: SA-PO1117]","volume":"23","author":"Ruggeri","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2215\/CJN.09250912","article-title":"Effects of dietary phosphate restriction and phosphate binders on FGF23 Levels in CKD","volume":"8","author":"Isakova","year":"2013","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0277|cit277","first-page":"45A","article-title":"Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR-OR068]","volume":"23","author":"Isakova","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1744-9987.2008.00557.x","article-title":"Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis","volume":"12","author":"Itoh","year":"2008","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub4-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/ndt\/10.12.2321","article-title":"Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients","volume":"10","author":"Janssen","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0280|cit280","first-page":"111","article-title":"Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients","volume":"45","author":"Janssen","year":"1996","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ndt\/6.2.98","article-title":"Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients","volume":"6","author":"Jespersen","year":"1991","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0282|cit282","first-page":"51","article-title":"Phosphate lowering to treat vascular dysfunction in CKD [abstract no: FR-OR040]","volume":"30","author":"Jovanovich","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub4-BIB0283|cit283","first-page":"708A","article-title":"Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU-PO569]","volume":"18","author":"Kakuta","year":"2007","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","article-title":"Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients","volume":"57","author":"Kakuta","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1744-9987.2012.01071.x","article-title":"Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis","volume":"16","author":"Kasai","year":"2012","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/089686080602600308","article-title":"Sevelamer hydrochloride versus aluminum hydroxide: Effect on serum phosphorus and lipids in CAPD patients","volume":"26","author":"Katopodis","year":"2006","journal-title":"Peritoneal Dialysis International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0287|cit287","first-page":"312A","article-title":"Impact of lanthanum carbonate on FGF23 in chronic kidney disease stages 3-5 [abstract no: TH-PO915]","volume":"23","author":"Khosla","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0288|cit288","first-page":"646A","article-title":"Impact of lanthanum carbonate on FGF23 in chronic kidney disease stages 3-5 [abstract no: SA-PO2285]","volume":"22","author":"Khosla","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0289|cit289","first-page":"240A","article-title":"Calcium carbonate is effective for decreasing phosphate loading and FGF-23 in stage 3 CKD [abstract no: TH-PO580]","volume":"25","author":"Kiattisunthorn","year":"2014","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0290|cit290","first-page":"64","article-title":"Efficacy of lanthanum carbonate and calcium carbonate in Korean dialysis patients","volume":"29","author":"Ko","year":"2010","journal-title":"Korean Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0291|cit291","first-page":"576a","article-title":"Phase III study to investigate the efficacy, safety, and tolerability of PA21 (sucroferric oxyhydroxide) compared with sevelamer hydrochloride in Japanese hemodialysis patients with hyperphosphatemia [abstract no: FR-PO910]","volume":"26","author":"Koiwa","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/nep.12891","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study","volume":"22","author":"Koiwa","year":"2017","journal-title":"Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0293|cit293","first-page":"B7","article-title":"Effect of phosphate binders on biochemical and vascular outcomes in patients with non-dialysis dependent CKD [abstract no: FR-PO1072]","volume":"28","author":"Kovesdy","year":"2017","journal-title":"Journal of the American Journal of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0294|cit294","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.ekir.2018.03.011","article-title":"Changes with lanthanum carbonate, calcium acetate, and phosphorus restriction in CKD: a randomized controlled trial","volume":"3","author":"Kovesdy","year":"2018","journal-title":"Kidney International Reports"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0295|cit295","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/1744-9987.14123","article-title":"Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: a post hoc analysis of the LANDMARK trial","volume":"28","author":"Kato","year":"2024","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10157-016-1310-8","article-title":"Design and baseline characteristics of the LANDMARK study","volume":"21","author":"Ogata","year":"2017","journal-title":"Clinical & Experimental Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub4-BIB0297|cit297","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10157-022-02270-5","article-title":"Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial","volume":"26","author":"Ogata","year":"2022","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0298|cit298","first-page":"B2","article-title":"Comparison of lanthanum carbonate and calcium carbonate in the cardiovascular mortality and morbidity of hemodialysis patients [abstract no: FR-OR146]","volume":"29","author":"Ogata","year":"2018","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"19","key":"10.1002\/14651858.CD006023.pub4-BIB0299|cit299","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1001\/jama.2021.4807","article-title":"Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial","volume":"325","author":"Ogata","year":"2021","journal-title":"JAMA"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0300|cit300","first-page":"962A","article-title":"Study design and baseline characteristics in the \"outcome study of lanthanum carbonate (LC) compared with calcium carbonate (CC) in hemodialysis (HD) patients (LANDMARK) study\" [abstract no: PUB322]","volume":"26","author":"Ogata","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5414\/CN107362","article-title":"Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study","volume":"79","author":"Lee","year":"2013","journal-title":"Clinical Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0302|cit302","first-page":"394A","article-title":"Effects of lanthanum carbonate compared with calcium carbonate on CAPD patients in Korea: a randomized prospective study [abstract no: FR-PO1216]","volume":"22","author":"Lee","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40620-014-0108-6","article-title":"Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Lee","year":"2015","journal-title":"Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN107630","article-title":"Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study","volume":"80","author":"Lemos","year":"2013","journal-title":"Clinical Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0929-6646(10)60107-6","article-title":"Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients","volume":"109","author":"Lin","year":"2010","journal-title":"Journal of the Formosan Medical Association \/ Taiwan Yi Zhi"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0306|cit306","first-page":"689A","article-title":"Potential advantages of sevelamer in terms of oxidative stress in maintenance hemodialysis patients with hyperphosphatemia [abstract no: SA-PO2560]","volume":"20","author":"Lin","year":"2009","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/11539120-000000000-00000","article-title":"Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study","volume":"31","author":"Lin","year":"2011","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12882-016-0245-3","article-title":"Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients","volume":"17","author":"Lin","year":"2016","journal-title":"BMC Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nep.12319","article-title":"Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients","volume":"19","author":"Lin","year":"2014","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0310|cit310","first-page":"467A","article-title":"Effect of sevelamer on homocysteinemia and lipid profile in patients undergoing maintenance hemodialysis - a randomized clinical trial [abstract no: F-PO610]","volume":"16","author":"Huang","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/08860220600925388","article-title":"A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients","volume":"28","author":"Liu","year":"2006","journal-title":"Renal Failure"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0312|cit312","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000531869","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer carbonate in Chinese dialysis patients with hyperphosphataemia: a randomised, open-label, multicentre, 12-week phase III study","volume":"148","author":"Liu","year":"2024","journal-title":"Nephron"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub4-BIB0313|cit313","first-page":"ii503","article-title":"A multi-centre, double-blind, randomised, placebo-controlled, multiple fixed-dose study of colestilan (MCI-196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]","volume":"27","author":"Dimkovic","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0314|cit314","first-page":"45A","article-title":"A multi-centre, double-blind, randomised,placebo-controlled, multiple fixed-dose study of colestilan (MCI-196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphatemia and dyslipidemia (DL): efficacy results [abstract no: FR-OR185]","volume":"22","author":"Locatelli","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/ndt\/gft064","article-title":"Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/ndt\/gft476","article-title":"The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study","volume":"29","author":"Locatelli","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0317|cit317","doi-asserted-by":"publisher","first-page":"574","DOI":"10.4103\/ijn.IJN_591_20","article-title":"Longitudinal study to find the association of serum phosphorus level with FGF23 in three different hyperphosphatemia management groups of stage 3 and 4 chronic kidney disease (CKD) patients","volume":"32","author":"Mahapatra","year":"2022","journal-title":"Indian Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0318|cit318","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000489964","article-title":"Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients","volume":"47","author":"Maruyama","year":"2018","journal-title":"American Journal of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0319|cit319","doi-asserted-by":"publisher","first-page":"iii679","DOI":"10.1093\/ndt\/gfx179.MP673","article-title":"MP673 Efficacy and safety of iron-based phosphate binders, ferric citrate hydrate versus sucroferric oxyhydroxide, on hyperphosphatemia in chronic hemodialysis patients [abstract]","volume":"32","author":"Matsushima","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0320|cit320","doi-asserted-by":"publisher","first-page":"i250","DOI":"10.1093\/ndt\/gfy104.FP619","article-title":"FP619 Long-term safety and efficacy of iron-based phosphate binders, ferric citrate hydrate versus sucroferricoxyhydroxide,on hyperphosphatemia in chronic hemodialysis patients [abstract]","volume":"33","author":"Matsushima","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0321|cit321","first-page":"1005A","article-title":"Comparison of efficacy and equivalent dose between osvaren and fosrenol for the control of serum phosphate in CAPD patients [abstract no: PUB496]","volume":"23","author":"Montenegro","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0322|cit322","first-page":"989A","article-title":"Peritoneal balances of Mg in peritoneal dialysis patients treated and not treated with oral Mg salts binders [abstract no: PUB425]","volume":"23","author":"Montenegro","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0323|cit323","first-page":"990A","article-title":"Peritoneal balances of calcium in peritoneal dialysis patients treated with and without oral calcium salts binders [abstract no: PUB428]","volume":"23","author":"Montenegro","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0324|cit324","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/pharmacy11010027","article-title":"Efficacy of lanthanum carbonate and sevelamer carbonate as phosphate binders in chronic kidney disease: a comparative clinical study","volume":"11","author":"Nain","year":"2023","journal-title":"Pharmacy"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0325|cit325","first-page":"97A","article-title":"Effect of phosphate binders in serum inflammatory profile, soluble CD14 and endotoxin levels in hemodialysis patients: a prospective, randomized, controlled trial [abstract no: SA-0R403]","volume":"22","author":"Navarro- Gonzalez","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2215\/CJN.01650211","article-title":"Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients","volume":"6","author":"Navarro-Gonzalez","year":"2011","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0327|cit327","unstructured":"A study of MCI-196 in chronic kidney disease stage V subjects on dialysis with hyperphosphatemia ClinicalTrials.gov\/show\/NCT00542815"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0328|cit328","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40265-019-01118-9","article-title":"Does the administration of sevelamer or nicotinamide modify uremic toxins or endotoxemia in chronic hemodialysis patients?","volume":"79","author":"Lenglet","year":"2019","journal-title":"Drugs"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfw042","article-title":"Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study","volume":"32","author":"Lenglet","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0330|cit330","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/ndt\/gfac206","article-title":"Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial","volume":"38","author":"Ketteler","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0331|cit331","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ekir.2020.12.012","article-title":"Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis: a randomized clinical trial","volume":"6","author":"Ketteler","year":"2021","journal-title":"KI Reports"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub4-BIB0332|cit332","first-page":"ii229","article-title":"Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium-based phosphate binder in patients on hemodialysis [abstract]","volume":"27","author":"Ohtake","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1074248413486355","article-title":"Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study","volume":"18","author":"Ohtake","year":"2013","journal-title":"Journal of Cardiovascular Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0334|cit334","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000490903","article-title":"Effect of sucroferric oxyhydroxide on fibroblast growth factor 23 levels in hemodialysis patients","volume":"140","author":"Otsuki","year":"2018","journal-title":"Nephron"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0335|cit335","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.34067\/KID.0002002021","article-title":"Safety and efficacy of tenapanor for long-term serum phosphate control in maintenance dialysis: a 52-week randomized phase 3 trial (PHREEDOM)","volume":"2","author":"Block","year":"2021","journal-title":"Kidney360"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1681\/ASN.20213210S16a","article-title":"Tenapanor controls serum phosphorus and reduces PTH and FGF-23 in patients on dialysis with severe secondary hyperparathyroidism [abstract no: TH-OR18]","volume":"32","author":"Weiner","year":"2021","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub4-BIB0337|cit337","first-page":"vi183","article-title":"Effective reduction of serum phosphorus using carbonate, with fewer tablets than sevelamer hydrochloride [abstract no: FP486]","volume":"22","author":"Pratt","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2369-15-71","article-title":"Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial","volume":"15","author":"Ure\u00f1a-Torres","year":"2014","journal-title":"BMC Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0339|cit339","first-page":"iii61","article-title":"A randomized, double-blind, placebo-controlled trial of the effect of calcium acetate on serum phosphorus (P) in non-dialysis-dependent patients with chronic kidney disease (NDD-CKD): the EPICK Study [abstract no: Sa104]","volume":"3","author":"Qunibi","year":"2010","journal-title":"NDT Plus"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2369-12-9","article-title":"A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease","volume":"12","author":"Qunibi","year":"2011","journal-title":"BMC Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10157-017-1504-8","article-title":"Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial","volume":"22","author":"Riccio","year":"2018","journal-title":"Clinical & Experimental Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0272-6386(89)80052-6","article-title":"Phosphate-binding effects of sucralfate in patients with chronic renal failure","volume":"13","author":"Roxe","year":"1989","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0343|cit343","first-page":"130","article-title":"Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double-blind placebo-controlled study","volume":"20","author":"Rudnicki","year":"1994","journal-title":"Mineral & Electrolyte Metabolism"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub4-BIB0344|cit344","first-page":"vi83","article-title":"Progression of coronary artery calcification in patients with chronic kidney disease. Role of phosphorus binders [abstract no: FP192]","volume":"22","author":"Russo","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","article-title":"The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer","volume":"72","author":"Russo","year":"2007","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ndt\/18.3.582","article-title":"Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study","volume":"18","author":"Sadek","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0347|cit347","first-page":"26","article-title":"Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis","volume":"19","author":"Saif","year":"2007","journal-title":"Journal of Ayub Medical College, Abbottabad"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0348|cit348","doi-asserted-by":"publisher","first-page":"1432\u201347","DOI":"10.1016\/j.ekir.2020.06.014","article-title":"Effect of sevelamer on calciprotein particles in haemodialysis patients: the Sevelamer versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) randomized controlled trial","volume":"5","author":"Smith","year":"2020","journal-title":"Kidney International Reports"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0349|cit349","first-page":"7B","article-title":"Early intervention in the CKD-MDB affects vascular function [abstract no: LB-PO3163]","volume":"22","author":"Seifert","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000353569","article-title":"Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease","volume":"38","author":"Seifert","year":"2013","journal-title":"American Journal of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0351|cit351","first-page":"iii196","article-title":"Sevelamer improves serum electrolyte profile, metabolic and cardiovascular markers and survival in ESRD patients on hemodialysis treatment [abstract no: Sa473]","volume":"3","author":"Sezer","year":"2010","journal-title":"NDT Plus"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0352|cit352","first-page":"833A","article-title":"Sevelamer improves serum electrolyte profile, metabolic and cardiovascular markers and survival in ESRD patients on hemodialysis treatment [abstract no: PUB104]","volume":"21","author":"Sezer","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0353|cit353","first-page":"58","article-title":"Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial","volume":"31","author":"Shahbazian","year":"2011","journal-title":"Nefrologia"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"785","DOI":"10.15537\/1658-3175.2445","article-title":"Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"25","author":"Shaheen","year":"2004","journal-title":"Saudi Medical Journal"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub4-BIB0355|cit355","first-page":"vi245","article-title":"A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone [abstract no: SAP245]","volume":"22","author":"Shibata","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0356|cit356","unstructured":"Shibata K Iwamoto T Ono S Murakami T Yanagi M Koguchi N A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone. Three-years follow up [abstract no: SU500] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5414\/CNP70404","article-title":"Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia","volume":"70","author":"Shigematsu","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0358|cit358","doi-asserted-by":"publisher","first-page":"iii1731","DOI":"10.1093\/ndt\/gfaa142.P1411","article-title":"P1411 The efficacy and safety of the sucrofferric oxyhydxide in hemodialysis patients: Results of a prospective randomized controlled trial [abstract]","volume":"35","author":"Shutov","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0359|cit359","first-page":"17","article-title":"The SLO-NIACIN trial: a double-blind placebo controlled trial of low dose slow-release niacin to lower phosphate in haemodialysis patients [abstract no: 010]","volume":"18","author":"Tan","year":"2013","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0360|cit360","first-page":"651","article-title":"Effects of lanthanum carbonate on serum calcium and phosphorus of CAPD patients with chronic renal failure receiving calcitriol pulse therapy due to secondary hyperparathyroidism","volume":"14","author":"Song","year":"2014","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0361|cit361","first-page":"634A","article-title":"Modulation of FGF23 by phosphate binders in chronic kidney disease stage 4 -5 predialysis (lanthanum vs calcium carbonate) [abstract no: SA-PO2241]","volume":"22","author":"Soriano","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CN107764","article-title":"The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients","volume":"80","author":"Soriano","year":"2013","journal-title":"Clinical Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub4-BIB0363|cit363","first-page":"v95","article-title":"Lanthanum carbonate - a novel phosphate binder in maintenance dialysis patients [abstract no: SP228]","volume":"20","author":"Sikole","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD006023.pub4-BIB0364|cit364","first-page":"67","article-title":"The use of lanthanum carbonate as a novel phosphate binder in maintenance dialysis patients [abstract no: M63]","volume":"17","author":"Sikole","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0365|cit365","first-page":"685","article-title":"The impact of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients - single center experience [abstract no: w436]","volume":"18","author":"Spasovski","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0366|cit366","first-page":"630","article-title":"The beneficial effect of lanthanum carbonate on low turnover bone disease in dialysis patients [abstract no: P40]","volume":"26","author":"Spasovski","year":"2003","journal-title":"International Journal of Artificial Organs"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0367|cit367","unstructured":"Spasovski G Sikole A Gelev S Masin J Freemont T Webster I The evolution of renal bone disease in dialysis patients - comparative effects of lanthanum carbonate and calcium carbonate treatment [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 105 6"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0368|cit368","first-page":"v376","article-title":"Comparative, bone biopsy-based, 3 years follow-up study in dialysis patients during and after 1 year treatment with lanthanum carbonate [abstract no: TO14]","volume":"20","author":"Spasovski","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub4-BIB0369|cit369","first-page":"741A","article-title":"The evolution of renal osteodystrophy in dialysis patients: comparative effects of lanthanum carbonate and calcium carbonate [abstract no: SA-PO842]","volume":"16","author":"Spasovski","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1492-7535.2003.01235.x","article-title":"Lanthanum carbonate in the management of renal osteodystrophy in dialysis patients [abstract]","volume":"7","author":"Spasovski","year":"2003","journal-title":"Hemodialysis International"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0372|cit372","first-page":"A56","article-title":"Magnesium carbonate - an effective phosphate binder [abstract no: 152]","volume":"47","author":"Spiegel","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.jrn.2007.08.005","article-title":"Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study","volume":"17","author":"Spiegel","year":"2007","journal-title":"Journal of Renal Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1542-4758.2009.00364.x","article-title":"Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study","volume":"13","author":"Spiegel","year":"2009","journal-title":"Hemodialysis International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"A90","DOI":"10.1053\/j.ajkd.2008.02.263","article-title":"Lanthanum carbonate reduces phosphate burden in patients with CKD stages 3 and 4: results from a randomized multicenter trial [abstract no: 252]","volume":"51","author":"Sprague","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2215\/CJN.02830608","article-title":"Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial","volume":"4","author":"Sprague","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub4-BIB0377|cit377","first-page":"927A","article-title":"Hyperphosphatemia in chronic kidney disease stages 3 and 4: findings from a randomized, multi-center trial [abstract no: PUB442]","volume":"18","author":"Sprague","year":"2007","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0378|cit378","first-page":"756A","article-title":"Comparative study between the impact of calcium acetate versus sevelamer carbonate on progression of vascular calcification in pre-end stage renal disease (CKD stage 4 and 5 ) patients [abstract no: SA-PO560]","volume":"24","author":"Sunder","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5414\/CN108269","article-title":"Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial","volume":"82","author":"Takahara","year":"2014","journal-title":"Clinical Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0380|cit380","first-page":"229","article-title":"Protein-bound uremic toxins lowering effect of sevelamer in pre-dialysis CKD patients with hyperphosphatemia: a randomized controlled trial [abstract no: TH-PO434]","volume":"30","author":"Takkavatakarn","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0381|cit381","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/toxins13100688","article-title":"Protein-bound uremic toxins lowering effect of sevelamer in pre-dialysis chronic kidney disease patients with hyperphosphatemia: a randomized controlled trial","volume":"13","author":"Takkavatakarn","year":"2021","journal-title":"Toxins"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0382|cit382","unstructured":"Tielmans C Knoop C Doutrelepont JM Timmermans D Even-Adin D Vanherweghem JL Superiority of calcium acetate (ACET) over carbonate (CARB) to bind phosphorus (P) in hemodialysis patients (HDP) [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 219A"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0383|cit383","first-page":"782A","article-title":"Comparison of lanthanum carbonate with calcium carbonate on biomarkers of bone turnover in hemodialysis patients: a cross-over study [abstract no: SA-PO2940]","volume":"21","author":"Toida","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5414\/CN107257","article-title":"Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study","volume":"78","author":"Toida","year":"2012","journal-title":"Clinical Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0385|cit385","first-page":"70","article-title":"Attenuation of aortic calcification with lanthanum carbonate vs calcium-based phosphate binders in haemodialysis - a randomized controlled trial [abstract no: 167]","volume":"15","author":"Toussaint","year":"2010","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1440-1797.2010.01412.x","article-title":"Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial","volume":"16","author":"Toussaint","year":"2011","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2215\/CJN.03410708","article-title":"Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients","volume":"4","author":"Toussaint","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s11255-014-0751-9","article-title":"Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study","volume":"46","author":"Tzanakis","year":"2014","journal-title":"International Urology and Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0389|cit389","first-page":"1005A","article-title":"Magnesium retards the progress of the artery calcifications in hemodialysis patients: a controlled prospective study [abstract no: PUB498]","volume":"23","author":"Tzanakis","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0390|cit390","first-page":"551A","article-title":"Sevelamer carbonate reduced advanced glycation endproducts inflammation, and glycated hemoglobin in a randomized controlled trial of patients with diabetic kidney disease [abstract no: FR-PO793]","volume":"25","author":"Harbord","year":"2014","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2215\/CJN.12891211","article-title":"Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease","volume":"7","author":"Vlassara","year":"2012","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0392|cit392","first-page":"18A","article-title":"Sevelamer carbonate improves metabolism and reduces risk factors for progressive nephropathy in type 2 diabetics with stage 2 - 4 CKD by sequestering oral advanced glycation end product [abstract no: TH-OR072]","volume":"22","author":"Vlassara","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2215\/CJN.07750814","article-title":"Effects of sevelamer carbonate on advanced glycation end products and antioxidant\/pro-oxidant status in patients with diabetic kidney disease","volume":"10","author":"Yubero-Serrano","year":"2015","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1744-9987.12153","article-title":"Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial","volume":"18","author":"Wada","year":"2014","journal-title":"Therapeutic Apheresis and Dialysis"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0395|cit395","first-page":"508","article-title":"Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients","volume":"35","author":"Wang","year":"2015","journal-title":"Journal of Huazhong University of Science and Technology. Medical Sciences"},{"issue":"11-12","key":"10.1002\/14651858.CD006023.pub4-BIB0396|cit396","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000534484","article-title":"Efficacy and safety of ferric citrate on hyperphosphatemia among Chinese patients with chronic kidney disease undergoing hemodialysis: a phase III multicenter randomized open-label active-drug-controlled study","volume":"54","author":"Wang","year":"2023","journal-title":"American Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0397|cit397","first-page":"793A","article-title":"Fermagate is a more potent binder compared to sevelamer HCI in ESRD patients on hemodialysis [abstract no: SA-PO667]","volume":"23","author":"Wilkie","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD","volume":"9","author":"Yokoyama","year":"2014","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0399|cit399","first-page":"752A","article-title":"The effect of JTT-751 (ferric citrate hydrate) on phosphorus and FGF-23 in chronic kidney disease [abstract no: SA-PO544]","volume":"24","author":"Yokoyama","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gft483","article-title":"A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis","volume":"29","author":"Yokoyama","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/089686080902900515","article-title":"The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients","volume":"29","author":"Young","year":"2009","journal-title":"Peritoneal Dialysis International"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0402|cit402","first-page":"1293","article-title":"Efficacy of sevelamer carbonate for hyperphosphatemia in patients with end-stage renal disease: a randomized controlled trial","volume":"14","author":"Zhao","year":"2014","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0403|cit403","first-page":"9","article-title":"The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients","volume":"64","author":"Zwiech","year":"2011","journal-title":"Wiadomosci Lekarskie"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0404|cit404","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.nefroe.2021.12.003","article-title":"Advantages of the use of citrate over acetate as a stabilizer in hemodialysis fluid: a randomized ABC-treat study","volume":"42","author":"Sequera","year":"2022","journal-title":"Nefrologia"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/0971-4065.98754","article-title":"Sevelamer carbonate experience in Indian end stage renal disease patients","volume":"22","author":"Abraham","year":"2012","journal-title":"Indian Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4103\/1319-2442.100865","article-title":"Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients","volume":"23","author":"Ahmadi","year":"2012","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/1744-9987.12202","article-title":"Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study","volume":"18 Suppl 2","author":"Akizawa","year":"2014","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0408|cit408","first-page":"830A","article-title":"A multi-center randomized double-blind placebo-controlled trial on chewing effect of a chitosan loaded gum HS219 for the control of serum phosphorous in maintenance hemodialysis (HD) patients [abstract no: PUB090]","volume":"21","author":"Akizawa","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1471-2369-15-98","article-title":"Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial","volume":"15","author":"Akizawa","year":"2014","journal-title":"BMC Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.20203110S1164a","article-title":"Efficacy and safety of add-on tenapanor to phosphate binders for refractory hyperphosphatemia in Japanese patients on hemodialysis: a phase 2, double-blind study [abstract no: PO0375]","volume":"31","author":"Akizawa","year":"2020","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Sept","key":"10.1002\/14651858.CD006023.pub4-BIB0411|cit411","first-page":"557A","article-title":"Lanthanum carbonate: a novel non-calcaemic phosphate binder in dialysis patients [abstract no: A2941]","volume":"11","author":"Al-Baaj","year":"2000","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ndt\/gfh693","article-title":"Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study","volume":"20","author":"Al-Baaj","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2369-14-40","article-title":"Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients","volume":"14","author":"Hutchison","year":"2013","journal-title":"BMC Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0414|cit414","first-page":"A113","article-title":"Lanthanum carbonate: a novel non-calcaemic phosphate binder in dialysis patients [abstract]","volume":"15","author":"Hutchison","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0415|cit415","first-page":"515A","article-title":"Efficacy of lanthanum carbonate in patients on peritoneal dialysis: an opportunity to improve nutrition? [abstract no: FR-PO1726]","volume":"22","author":"Wilson","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0416|cit416","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1681\/ASN.20203110S1166c","article-title":"Long-term safety and efficacy of tenapanor for the control of serum phosphorus in patients with CKD on dialysis [abstract no: PO0384]","volume":"31","author":"Chertow","year":"2020","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0417|cit417","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1681\/ASN.2020101398","article-title":"A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY)","volume":"32","author":"Pergola","year":"2021","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1053\/j.ajkd.2020.02.316","article-title":"Efficacy of tenapanor for the control of serum phosphorus in patients with CKD on dialysis: novel mechanism of action allows for both monotherapy and dual mechanism approach [abstract no: 314]","volume":"75","author":"Rosenbaum","year":"2020","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.20203110S1164b","article-title":"Tolerability of tenapanor, an investigational, first-in-class, non-binder therapy for the control of serum phosphorus in patients with CKD on dialysis [abstract no: PO0376]","volume":"31","author":"Rosenbaum","year":"2020","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1681\/ASN.20203110S1163d","article-title":"Efficacy of tenapanor for the control of serum phosphorus in patients with CKD on dialysis: novel mechanism of action allows for both monotherapy and dual-mechanism approach [abstract no: PO0374]","volume":"31","author":"Rosenbaum","year":"2020","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.jrn.2004.04.004","article-title":"Calcium-enriched bread for treatment of uremic hyperphosphatemia","volume":"14","author":"Babarykin","year":"2004","journal-title":"Journal of Renal Nutrition"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0422|cit422","first-page":"680","article-title":"Role of chetoanalogues on calcium-phosphate metabolism and anemia of haemodialysis patients: a pilot controlled randomized study [abstract]","volume":"18","author":"Bigi","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2369-13-49","article-title":"Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial","volume":"13","author":"Bleskestad","year":"2012","journal-title":"BMC Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0424|cit424","first-page":"395a","article-title":"A randomized cross-over trial evaluating FG723 and PTH in the treatment of CKD stage 3b [abstract no: FR-PO1221]","volume":"22","author":"Bleskestad","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0425|cit425","first-page":"i156","article-title":"Effect of chitosan loaded chewing gum on serum phosphate in CKD [abstract]","volume":"28","author":"Block","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1-2","key":"10.1002\/14651858.CD006023.pub4-BIB0426|cit426","first-page":"93","article-title":"Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease","volume":"123","author":"Block","year":"2013","journal-title":"Nephron"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0427|cit427","first-page":"348","article-title":"A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis","volume":"20","author":"Borrego","year":"2000","journal-title":"Nefrologia"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0428|cit428","first-page":"165","article-title":"Safety, efficacy, and cost-effectiveness of Mg\/AI type hydrotalcite drug versus conventional phosphate binders in hemodialysis CKD patients with hyperphosphatemia [abstract no: TH-PO204]","volume":"29","author":"Chen","year":"2018","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0272-6386(97)90009-3","article-title":"Poly(allylamine hydrochloride) (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure","volume":"29","author":"Chertow","year":"1997","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5414\/CNP63461","article-title":"Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease","volume":"63","author":"Chiang","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0431|cit431","first-page":"142","article-title":"The novel phosphate binder lanthanum carbonate is preferred to conventional agents in a Chinese population [abstract]","volume":"31","author":"Webster","year":"2004","journal-title":"Nephrology Nursing Journal"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0432|cit432","first-page":"204A","article-title":"Efficacy and safety of lanthanum carbonate in the treatment of hyperphosphatemia in Chinese chronic renal failure patients [abstract no: F-PO652]","volume":"14","author":"Yang","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub4-BIB0433|cit433","first-page":"vi362","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of the effects of ferric citrate in patients undergoing hemodialysis [abstract no: SaP381]","volume":"22","author":"Chiang","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0434|cit434","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/joneph\/20.6.674","article-title":"Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources","volume":"20","author":"Chow","year":"2007","journal-title":"Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0435|cit435","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s10157-018-1584-0","article-title":"Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method","volume":"22","author":"Ito","year":"2018","journal-title":"Clinical and Experimental Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1590\/S1516-31802000000600006","article-title":"Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients","volume":"118","author":"D'Almeida Filho","year":"2000","journal-title":"Revista Paulista de Medicina [Sao Paulo Medical Journal]"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0437|cit437","first-page":"371","article-title":"Effect of an individualized therapy for hyperphosphatemia in hemodialysis patients - a single-center, open label randomized clinical trial [abstract no: TH-PO1038]","volume":"28","author":"Dong","year":"2017","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1053\/j.ajkd.2012.11.041","article-title":"Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial","volume":"61","author":"Dwyer","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0439|cit439","first-page":"630","article-title":"Effect of dietary phosphate restriction in pre-dialysis chronic kidney disease patients with hyperphosphataemia in Southern Nigeria","volume":"41","author":"Edeki","year":"2024","journal-title":"West African Journal of Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0440|cit440","doi-asserted-by":"publisher","first-page":"iii590","DOI":"10.1093\/ndt\/gfv199.09","article-title":"SP643 Sevelamer carbonate vs. lanthanum carbonate vs. calcium acetate\/magnesium carbonate in CKD patients on hemodialysis: a randomized study [abstract]","volume":"30","author":"Ekart","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0441|cit441","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00467-015-3208-1","article-title":"Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis","volume":"31","author":"El Borolossy","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0272-6386(12)80496-3","article-title":"Calcium acetate control of serum phosphorus in hemodialysis patients","volume":"17","author":"Emmett","year":"1991","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0443|cit443","first-page":"449","article-title":"Calcium acetate control of serum phosphorus in hemodialysis patients [abstract]","volume":"37","author":"Emmett","year":"1990","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0444|cit444","first-page":"530","article-title":"Intradialytic calcium balances with different calcium dialysate levels. Effects on cardiovascular stability and parathyroid function","volume":"72","author":"Fabrizi","year":"1996","journal-title":"Nephron"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub4-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1093\/ndt\/gfp372","article-title":"A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis","volume":"24","author":"Fan","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0446|cit446","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00467-017-3787-0","article-title":"Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease","volume":"33","author":"Fathallah-Shaykh","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0447|cit447","first-page":"304A","article-title":"Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease [abstract no: TH-PO905]","volume":"27","author":"Fathallah-Shaykn","year":"2016","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5414\/CNP62193","article-title":"Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis","volume":"62","author":"Finn","year":"2004","journal-title":"Clinical Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0449|cit449","first-page":"685","article-title":"Long-term treatment with lanthanum carbonate (Fosrenol) is safe and effective in haemodialysis patients [abstract no: W434]","volume":"18","author":"Finn","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0450|cit450","first-page":"A29","article-title":"Lanthanum carbonate (FosrenolTM) significantly reduces serum phosphorus levels and calcium X phosphorus product values in a dose-ranging study [abstract no: PS1-20]","volume":"8","author":"Finn","year":"2003","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1185\/030079905X41453","article-title":"A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis","volume":"21","author":"Finn","year":"2005","journal-title":"Current Medical Research and Opinion"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub4-BIB0452|cit452","first-page":"v93","article-title":"A randomized, cross-over study to compare once a day with three times per day sevelamer dosing [abstract no: SP221]","volume":"20","author":"Fischer","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0453|cit453","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1053\/j.ajkd.2006.05.026","article-title":"Results of a randomized crossover study comparing once daily and thrice-daily sevelamer dosing","volume":"48","author":"Fischer","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0454|cit454","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2215\/CJN.04741107","article-title":"Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study","volume":"3","author":"Mehrotra","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0455|cit455","first-page":"iv147","article-title":"A new formulation of lanthanum carbonate is preferred by patients and physicians [abstract no: SP396]","volume":"21","author":"Mehrotra","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0456|cit456","first-page":"356A","article-title":"Efficacy and safety of higher-strength lanthanum carbonate [abstract no: F-PO095]","volume":"17","author":"Mehrotra","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0457|cit457","first-page":"732A","article-title":"Patient and physician preference and satisfaction with a new formulation of lanthanum carbonate (LC) [abstract no: SA-PO803]","volume":"16","author":"Mehrotra","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0458|cit458","first-page":"356A","article-title":"Preference and satisfaction with reformulated higher-dosage strength lanthanum carbonate [abstract no: F-PO094]","volume":"17","author":"Mehrotra","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5414\/NHP35127","article-title":"Efficacy of aluminum hydrochloride and aluminum hydroxide of lowering plasma phosphate concentrations in patients with chronic renal insufficiency","volume":"35","author":"Friedrich","year":"2006","journal-title":"Nieren und Hochdruckkrankheiten"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0460|cit460","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10157-013-0815-7","article-title":"Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage v Japanese patients on maintenance renal replacement therapy","volume":"18","author":"Fukagawa","year":"2014","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0461|cit461","first-page":"4B","article-title":"A double-blind, randomized, placebo-controlled multicenter trial to compare the phosphate lowering efficacy of different doses of the iron-based phosphate binder SBR759 to placebo [abstract no: LB-PO3152]","volume":"22","author":"Junge","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40620-018-00571-1","article-title":"Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease","volume":"32","author":"Gao","year":"2019","journal-title":"Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0463|cit463","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00467-020-04805-y","article-title":"Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease","volume":"36","author":"Greenbaum","year":"2021","journal-title":"Pediatric Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0464|cit464","doi-asserted-by":"publisher","first-page":"iii591","DOI":"10.1093\/ndt\/gfv199.12","article-title":"SP646 Use of calcium carbonate emulsion for the treatment of hyperphosphatemia on chronic hemodialysis patients reduces total elemental calcium dose [abstract]","volume":"30","author":"Guinsburg","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0465|cit465","doi-asserted-by":"publisher","first-page":"iii597","DOI":"10.1093\/ndt\/gfv199.28","article-title":"SP662 Evaluating the efficacy of calcium carbonate emulsion (CCE) for the treatment of hyperphosphatemia in patients on chronic hemodialysis [abstract]","volume":"30","author":"Guinsburg","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0466|cit466","doi-asserted-by":"publisher","first-page":"iii599","DOI":"10.1093\/ndt\/gfv199.37","article-title":"SP671 Evaluating adherence to calcium carbonate emulsion (CCE) versus calcium carbonate tablets (CCT) for the treatment of hyperphosphatemia in patients on chronic hemodialysis [abstract]","volume":"30","author":"Guinsburg","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0467|cit467","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1007\/s00467-022-05492-7","article-title":"A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial","volume":"37","author":"Hanudel","year":"2022","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0468|cit468","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000431289","article-title":"Randomized, double-blind, placebo-controlled, withdrawal study of colestilan after dose titration in chronic kidney disease dialysis patients with hyperphosphatemia","volume":"130","author":"Hertel","year":"2015","journal-title":"Nephron"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0469|cit469","first-page":"538A","article-title":"Colestilan (MCI-196), a new calcium-free phosphate binder, is safe and effective in stage 5 CKD dialysis patients: Phase 3, randomized, double-blind (DB), placebo(PBO)-controlled, multicenter study [abstract no: F-PO1862]","volume":"21","author":"Hertel","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0470|cit470","first-page":"4A","article-title":"Effects of calcium carbonate supplement on phosphate balance and homeostasis in patients with stage 3 and 4 chronic kidney disease [abstract no: TH-OR015 ]","volume":"22","author":"Hill","year":"2011","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0471|cit471","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0472|cit472","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.kint.2020.09.035","article-title":"EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a Phase 1b randomized cross-over trial in hemodialysis patients","volume":"99","author":"Hill Gallant","year":"2021","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0473|cit473","first-page":"50","article-title":"EOS789, a novel pan-inhibitor of NaPi-IIb\/PiT-1\/PiT-2, decreased intestinal phosphate absorption in hemodialysis patients measured by sensitive and direct method using 33P: a phase 1b clinical trial [abstract no: FR-OR033]","volume":"30","author":"Moe","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0474|cit474","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.ajkd.2020.10.008","article-title":"Design and rationale of HiLo: a pragmatic, randomized trial of phosphate management for patients receiving maintenance hemodialysis","volume":"77","author":"Edmonston","year":"2021","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0475|cit475","first-page":"538A","article-title":"Phosphate binding efficacy of chewed vs. crushed lanthanum carbonate in hemodialysis patients [abstract no: F-PO1865]","volume":"20","author":"How","year":"2009","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0476|cit476","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1542-4758.2010.00509.x","article-title":"Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients","volume":"15","author":"How","year":"2011","journal-title":"Hemodialysis International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0477|cit477","first-page":"i470","article-title":"A randomized, open-label, crossover design study to compare the safety and efficacy of sevelamer carbonate versus calcium carbonate in the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis [abstract no: MP548]","volume":"28","author":"Ibrahim","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0478|cit478","doi-asserted-by":"crossref","first-page":"B66","DOI":"10.1053\/j.ajkd.2010.02.144","article-title":"Short-term effect of dietary phosphorus restriction and lanthanum carbonate on FGF23 in chronic kidney disease patients [abstract no: 137]","volume":"55","author":"Isakova","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0479|cit479","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ndt\/gfq419","article-title":"Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease","volume":"26","author":"Isakova","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0480|cit480","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11255-022-03287-1","article-title":"Iron absorption and phosphate-lowering effects of ferric citrate hydrate are not influenced by gastric acid secretion inhibitors in patients with chronic kidney disease: a retrospective post hoc analysis","volume":"55","author":"Ito","year":"2023","journal-title":"International Urology & Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01666818","article-title":"Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia","volume":"69","author":"Ittel","year":"1991","journal-title":"Klinische Wochenschrift"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0482|cit482","first-page":"1007A","article-title":"\"Binder Reminders\" for persistent hyperphosphatemia in hemodialysis patients: a fellow's quality improvement product [abstract no: PUB154]","volume":"26","author":"Jammalamadaka","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0483|cit483","first-page":"686","article-title":"Lanthanum carbonate (fosrenol) causes significant reductions in serum phosphorus and ca x p product in a dose-ranging, placebo-controlled study [abstract no: w437]","volume":"18","author":"Finn","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub4-BIB0484|cit484","first-page":"261A","article-title":"Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis [abstract no: A1317]","volume":"10","author":"Finn","year":"1999","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub4-BIB0485|cit485","first-page":"263A","article-title":"Safety of an investigational phosphate binder (lanthanum carbonate) in hemodialysis patients [abstract no: A1327]","volume":"10","author":"Joy","year":"1999","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0486|cit486","first-page":"150","article-title":"Efficacy and tolerability of lanthanum carbonate, a new phosphate binder for the treatment of hyperphosphatemia [abstract]","volume":"30","author":"Finn","year":"2003","journal-title":"Nephrology Nursing Journal"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0487|cit487","first-page":"151","article-title":"Lanthanum carbonate, a novel phosphate binder, is effective and has a good safety profile in the long-term treatment of hyperphosphatemia in end-stage renal disease [abstract]","volume":"30","author":"Finn","year":"2003","journal-title":"Nephrology Nursing Journal"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0488|cit488","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1185\/030079905X41453","article-title":"A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis","volume":"21","author":"Finn","year":"2005","journal-title":"Current Medical Research & Opinion"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","article-title":"Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia","volume":"42","author":"Joy","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0490|cit490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN106830","article-title":"Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study","volume":"78","author":"Kalil","year":"2012","journal-title":"Clinical Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0491|cit491","first-page":"399a","article-title":"The effect of lanthanum carbonate (LC) (fosrenol) on coronary artery calcification (CAC) and endothelial function (FMD) in hemodialysis (HD) patients. A pilot, prospective study [abstract no: F-PO1252]","volume":"20","author":"Kalil","year":"2009","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0492|cit492","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients","volume":"9","author":"Koiwa","year":"2005","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0493|cit493","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1744-9987.2005.00294.x","article-title":"Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan","volume":"9","author":"Koiwa","year":"2005","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10157-016-1299-z","article-title":"Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study","volume":"21","author":"Koiwa","year":"2017","journal-title":"Clinical & Experimental Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0495|cit495","doi-asserted-by":"crossref","first-page":"A68","DOI":"10.1016\/j.krcp.2012.04.527","article-title":"Fosrenol for enhancing dietary protein intake in hypoalbuminemic dialysis patients (FREDI) study [abstract]","volume":"31","author":"Koontz","year":"2012","journal-title":"Kidney Research & Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ndt\/gfh632","article-title":"Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial","volume":"20","author":"Kurihara","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0497|cit497","first-page":"206A","article-title":"Effect of MCI-196 (colestilan) on hyperphosphatemia in hemodialysis patients [abstract no: F-PO662]","volume":"14","author":"Kurihara","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0498|cit498","first-page":"e284","article-title":"Changes in serum fibroblast growth factor 23 during the use of calcium carbonate concurrent with calcitriol in stage 3 CKD patients [abstract no: 341]","volume":"33","author":"Lee","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0499|cit499","doi-asserted-by":"publisher","first-page":"e0264727","DOI":"10.1371\/journal.pone.0264727","article-title":"Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: a multicenter, open-label, phase IV trial","volume":"17","author":"Lee","year":"2022","journal-title":"PLOS One [Electronic Resource]"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0500|cit500","doi-asserted-by":"publisher","first-page":"69","DOI":"10.23876\/j.krcp.2018.37.1.69","article-title":"Effects of education on low-phosphate diet and phosphate binder intake to control serum phosphate among maintenance hemodialysis patients: a randomized controlled trial","volume":"37","author":"Lim","year":"2018","journal-title":"Kidney Research & Clinical Practice"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub4-BIB0501|cit501","first-page":"272A","article-title":"MCI-196, a new phosphate binder, has an additional effect on dyslipidemia and uric acid in patients with hyperphosphatemia on hemodialysis [abstract no: F-PO952]","volume":"15","author":"Locatelli","year":"2004","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub4-BIB0502|cit502","first-page":"272A","article-title":"MCI-196, a new phosphate binder, reduces hyperphosphatemia in hemodialysis patients: a phase II, dose-finding study [abstract no: F-PO953]","volume":"15","author":"Locatelli","year":"2004","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ndt\/gfp445","article-title":"Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study","volume":"25","author":"Locatelli","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub4-BIB0504|cit504","first-page":"v5","article-title":"MCI-196, a new phosphate binder, reduces hyperphosphataemia and lipid levels in patients on regular hemodialysis [abstract no: SO08]","volume":"20","author":"Locatelli","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0505|cit505","first-page":"384","article-title":"Calcium acetate (CaAc), an effective binder of dietary phosphorus (P) in patients with chronic renal failure (CRF) [abstract]","volume":"35","author":"Mai","year":"1989","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0506|cit506","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ki.1989.247","article-title":"Calcium acetate, an effective phosphorus binder in patients with renal failure","volume":"36","author":"Mai","year":"1989","journal-title":"Kidney International"},{"issue":"6496","key":"10.1002\/14651858.CD006023.pub4-BIB0507|cit507","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bmj.291.6496.623","article-title":"Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide","volume":"291","author":"Mak","year":"1985","journal-title":"British Medical Journal Clinical Research Ed"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0508|cit508","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2147\/TCRM.S330649","article-title":"Different effect of lanthanum carbonate and sevelamer hydrochloride on calcium balance in patients with moderate to advanced chronic kidney disease","volume":"17","author":"Makowka","year":"2021","journal-title":"Therapeutics & Clinical Risk Management"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0509|cit509","first-page":"367A","article-title":"A phase 2, randomized, double-blind,placebo-controlled, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia [abstract no: F-PO1108]","volume":"20","author":"Martin","year":"2009","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0510|cit510","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ekir.2020.12.017","article-title":"NaPi-IIb inhibition for hyperphosphatemia in chronic kidney disease hemodialysis patients","volume":"6","author":"Maruyama","year":"2021","journal-title":"Kidney International Reports"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0511|cit511","first-page":"797","article-title":"Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism","volume":"112","author":"Matuszkiewicz-Rowinska","year":"2004","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub4-BIB0512|cit512","first-page":"vi171","article-title":"Iron-magnesium hydroxycarbonate (alpharen): a novel non calcium containing phosphate binder for the treatment of hyperphosphataemia in chronic haemodialysis patients [abstract no: FP452]","volume":"22","author":"McIntyre","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0513|cit513","first-page":"359A","article-title":"Alpharen is a novel effective non calcium containing phosphate binder for the treatment of hyperphosphataemia in chronic haemodialysis patients [abstract no: F-PO108]","volume":"17","author":"McIntyre","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"A60","DOI":"10.1053\/j.ajkd.2007.02.148","article-title":"Iron-magnesium hydroxycarbonate (alpharen): a novel non calcium containing phosphate binder for the treatment of hyperphosphataemia in chronic haemodialysis patients [abstract no: 142]","volume":"49","author":"McIntyre","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0515|cit515","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2215\/CJN.02630608","article-title":"Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients","volume":"4","author":"McIntyre","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub4-BIB0516|cit516","first-page":"612A","article-title":"Ferric citrate (FC), an alternate phosphorous (PHS)-binder in ESRD patients on hemodialysis (HD) [abstract no: A3098]","volume":"10","author":"Messana","year":"1999","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0517|cit517","first-page":"818","article-title":"Treatment of hyperparathyroidism in dialysis patients by intravenous 1alpha OH vitamin D3 in association with MG(OH)2 as sole phophate binder [abstract]","volume":"6","author":"Moriniere","year":"1991","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0518|cit518","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000186732","article-title":"Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +\/- Mg(OH)2","volume":"60","author":"Morniere","year":"1992","journal-title":"Nephron"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0519|cit519","first-page":"iii236","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis [abstract no: Sa578]","volume":"3","author":"Moustafa","year":"2010","journal-title":"NDT Plus"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0520|cit520","first-page":"141","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis","volume":"7","author":"Moustafa","year":"2014","journal-title":"International Journal of Nephrology & Renovascular Disease"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub4-BIB0521|cit521","first-page":"ii176","article-title":"Dose dependent reduction of cytotoxic advanced glycation endproducts by sevelamer carbonate [abstract]","volume":"27","author":"Striker","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0522|cit522","first-page":"i488","article-title":"Methylglyoxal (MG) levels are markedly higher in diabetic hemodialysis (HD) patients than non-diabetic HD patients, which may contribute to increased morbidity and mortality in diabetics [abstract no: MP599]","volume":"28","author":"Striker","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0523|cit523","first-page":"752A","article-title":"A dose-response study to determine the minimal dose of sevelamer carbonate that reduces cardiovascular disease risk factors in type 2 diabetic hemodialysis patients [abstract no: SA-PO499]","volume":"23","author":"Striker","year":"2012","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0524|cit524","unstructured":"Mouzo R Sierra FG Lombardi V Rodriguez J Castro P Alvarez A Effectiveness of sevelamer (SEV) administration according to Hispanic dietary habits and phosphate food content in hemodialysis chronic (HD) patients [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 104"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0525|cit525","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10157-023-02406-1","article-title":"Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial","volume":"28","author":"Nakayama","year":"2024","journal-title":"Clinical & Experimental Nephrology"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0526|cit526","unstructured":"Parathyroid hormone levels in relation to the phosphorus content of meals https:\/\/www.clinicaltrials.gov\/study\/NCT00018135"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0527|cit527","unstructured":"Arterial stiffness and calcifications in haemodialysis patients on sevelamer or calcium acetate https:\/\/www.clinicalTrials.gov\/show\/NCT00364000"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0528|cit528","unstructured":"Dose ranging study of magnesium iron hydroxycarbonate in haemodialysis subjects with hyperphosphataemia https:\/\/www.clinicalTrials.gov\/show\/NCT00436683"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0529|cit529","unstructured":"Chewed vs. crushed lanthanum carbonate in hemodialysis patients https:\/\/www.clinicalTrials.gov\/show\/NCT00660530"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0530|cit530","unstructured":"Sevelamer hydrochloride in peritoneal dialysis patients (SERENE) https:\/\/www.clinicaltrials.gov\/show\/NCT00745589"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0531|cit531","unstructured":"Equivalence of calcium acetate oral solution and sevelamer carbonate tablets in hemodialysis patients (COS-002) https:\/\/www.clinicaltrials.gov\/show\/NCT01427907"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0532|cit532","unstructured":"Effect of phosphate binders on FGF-23 with concurrent calcitriol https:\/\/www.clinicaltrials.gov\/show\/NCT01748396"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0533|cit533","unstructured":"Therapeutic equivalence of OsvaRen\u00ae tablets and OsvaRen\u00ae granules (OsvaRenNEW) https:\/\/www.clinicaltrials.gov\/show\/NCT02027662"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0534|cit534","unstructured":"Ferric citrate for the transition from CKD stage 4\/\u200b5 to CKD stage 5D (05D) https:\/\/www.clinicaltrials.gov\/show\/NCT02492620"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0535|cit535","unstructured":"Study of individualized therapy on hyperphosphatemia in maintenance hemodialysis patients https:\/\/www.clinicaltrials.gov\/show\/NCT02684643"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0536|cit536","unstructured":"The efficacy of niacin on hyperphosphatemia in patients undergoing haemodialysis https:\/\/www.clinicaltrials.gov\/show\/NCT03163576"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0537|cit537","unstructured":"DS2330b alone and with sevelamer in patients on chronic hemodialysis https:\/\/www.clinicaltrials.gov\/show\/NCT03305471"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0538|cit538","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1774-9987.2005.00212.x","article-title":"Control of parathyroid function in patients with a short history of hemodialysis","volume":"9","author":"Nishi","year":"2005","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0539|cit539","first-page":"121","article-title":"Bone histomorphometry and biochemical comparison between asymptomatic patients on maintenance dialysis with and without hyperaluminaemia [abstract]","volume":"1","author":"Noel","year":"1986","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0540|cit540","first-page":"774A","article-title":"Wnt pathway inhibition: another actor in CKD-MBD pathophysiology? [abstract no: SA-PO2908]","volume":"21","author":"Graciolli","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0541|cit541","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0542|cit542","first-page":"532A","article-title":"Sevelamer (SEV), but not calcium acetate (CA), lowers fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) patients [abstract no: SA-PO862]","volume":"18","author":"Oliveira","year":"2007","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0543|cit543","first-page":"833A","article-title":"CKD is associated with increased serum levels of energy-regulating hormones [abstract no: PUB102]","volume":"21","author":"Oliveira","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0544|cit544","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/ndt\/gft234","article-title":"Disturbances of Wnt\/beta-catenin pathway and energy metabolism in early CKD: effect of phosphate binders","volume":"28","author":"Oliveira","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0545|cit545","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0546|cit546","doi-asserted-by":"publisher","first-page":"732","DOI":"10.34067\/KID.0000000000000387","article-title":"Tenapanor as therapy for hyperphosphatemia in maintenance dialysis patients: results from the OPTIMIZE study","volume":"5","author":"Sprague","year":"2024","journal-title":"Kidney360"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0547|cit547","first-page":"924A","article-title":"Does simultaneous administration of sevelamer and calcium carbonate decrease phosphate-binding capacity? [abstract no: PUB429]","volume":"18","author":"Ouellet","year":"2007","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0548|cit548","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1744-9987.2009.00748.x","article-title":"Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?","volume":"14","author":"Ouellet","year":"2010","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0549|cit549","unstructured":"Pai P Ross C Wilkie M Warwick G Chapman A McIntyre C Fermagate (Alpharen) provides long term effective control of serum phosphate combined with good tolerability [abstract no: SU609] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub4-BIB0550|cit550","first-page":"732A","article-title":"Fermagate (AlpharenT): a novel anion exchange compound, effectively controls hyperphosphatemia in patients on hemodialysis [abstract no: SA-PO2751]","volume":"19","author":"Pai","year":"2008","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0551|cit551","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/cpdd.1336","article-title":"Effect of the phosphate binder sevelamer carbonate on the bioavailability of enarodustat, an oral erythropoiesis stimulating agent","volume":"13","author":"Pai","year":"2024","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0552|cit552","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1016\/j.ekir.2019.05.906","article-title":"Study of calcium carbonate versus sevelamer on vascular stiffness in haemodialysis patients [abstract no: MON-116]","volume":"4","author":"Pan","year":"2019","journal-title":"Kidney International Reports"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0553|cit553","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/j.ekir.2020.02.620","article-title":"SUN-094 A randomised cross-over trial of the effects of calcium carbonate and sevelamer phosphate binders on calciprotein particles in prevalent haemodialysis patients [abstract]","volume":"5","author":"Pan","year":"2020","journal-title":"Kidney International Reports"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0554|cit554","first-page":"177","article-title":"Symptom burden with calcium carbonate compared to sevelamer in haemodialysis patients [abstract no: TH-PO242]","volume":"30","author":"Pan","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0555|cit555","first-page":"576A","article-title":"Efficacy and safety of PT20:a novel iron-based phosphate binder [abstract no: FR-PO909]","volume":"26","author":"Block","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0556|cit556","doi-asserted-by":"publisher","first-page":"1399\u2013407","DOI":"10.1093\/ndt\/gfaa116","article-title":"Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, phase IIb study in patients with haemodialysis-dependent chronic kidney disease","volume":"36","author":"Sampson","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0557|cit557","first-page":"1301","article-title":"Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis [abstract]","volume":"8","author":"Pflanz","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0558|cit558","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/ndt\/9.8.1121","article-title":"Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis","volume":"9","author":"Pflanz","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5-6","key":"10.1002\/14651858.CD006023.pub4-BIB0559|cit559","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000065273","article-title":"Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure","volume":"22","author":"Phelps","year":"2002","journal-title":"American Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0560|cit560","first-page":"1032A","article-title":"Determinants of [FGF23] in stages 3-4 CKD [abstract no: PUB600]","volume":"25","author":"Phelps","year":"2014","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0561|cit561","article-title":"Use of sevelamer carbonate to examine the role of intraluminal phosphate in secondary hyperparathyroidism [abstract no: SA-PO579]","volume":"24","author":"Phelps","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CN108227","article-title":"Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism","volume":"82","author":"Phelps","year":"2014","journal-title":"Clinical Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub4-BIB0563|cit563","doi-asserted-by":"publisher","first-page":"v80","DOI":"10.1093\/ndt\/20.suppl_5.v79","article-title":"Alfacalcidol is essential for bone mineral density in chronic renal failure [abstract no: SP184]","volume":"20","author":"Przedlacki","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0564|cit564","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.ndt.a092467","article-title":"Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study","volume":"8","author":"Ring","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0565|cit565","first-page":"369","article-title":"Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: a randomized double-blind placebo-controlled study","volume":"65","author":"Rudnicki","year":"1993","journal-title":"Nephron"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub4-BIB0566|cit566","first-page":"936A","article-title":"Randomzied, open-label, cross-over study to assess the potential pharmacokinetic interaction of warfarin and sevelamer carbonate [abstract no: PUB555]","volume":"19","author":"Ruff","year":"2008","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0567|cit567","first-page":"328","article-title":"Prospective assessment of aluminum retention in dialyzed patients given calcium carbonate or aluminum hydroxide [abstract]","volume":"37","author":"Goodman","year":"1990","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0568|cit568","first-page":"451","article-title":"Prospective trial of calcium carbonate versus aluminum hydroxide with oral calcitriol therapy in renal osteodystrophy [abstract]","volume":"37","author":"Salusky","year":"1990","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0569|cit569","unstructured":"Salusky IB Foley J Goodman WG Calcium carbonate versus aluminum hydroxide with oral calcitriol therapy in pediatric renal osteodystrophy [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 416A"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0570|cit570","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM199102213240804","article-title":"Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease","volume":"324","author":"Salusky","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0571|cit571","first-page":"134A","article-title":"Differential effect of doxercalciferol and calcitriol on skeletal lesions of secondary hyperparathyroidism [abstract no: TH-PO133]","volume":"17","author":"Pereira","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0572|cit572","first-page":"202A","article-title":"Skeletal response to the treatment of secondary hyperparathyroidism: a comparison between calcitriol and 1-alpha-D2 [abstract no: F-PO643]","volume":"14","author":"Salusky","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub4-BIB0573|cit573","first-page":"281A","article-title":"Prospective comparison of calcium-based binder versus sevelamer HCL on the control of the skeletal lesions of secondary hyperparathyroidism [abstract no: F-PO989]","volume":"15","author":"Salusky","year":"2004","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0574|cit574","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1681\/ASN.2004100885","article-title":"Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols","volume":"16","author":"Salusky","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0575|cit575","first-page":"206A","article-title":"A prospective assessment of sevelamer hydrochloride versus calcium carbonate in dialyzed children [abstract no: F-PO661]","volume":"14","author":"Salusky","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0576|cit576","first-page":"134A","article-title":"Effects of vitamin D therapy on FGF-23, PTH and the skeletal lesions of secondary hyperparathyroidism [abstract no: TH-PO132]","volume":"17","author":"Wesseling","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0577|cit577","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00467-009-1143-8","article-title":"Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols","volume":"24","author":"Wesseling-Perry","year":"2009","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0578|cit578","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0579|cit579","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/0253-7613.56074","article-title":"Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease","volume":"41","author":"Scaria","year":"2009","journal-title":"Indian Journal of Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0580|cit580","first-page":"734","article-title":"The effect of calcium acetate and calcitriol on the calcium and phosphorus metabolism in haemodialysis patients [abstract]","volume":"5","author":"Schaefer","year":"1990","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0581|cit581","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ndt\/6.3.170","article-title":"The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study","volume":"6","author":"Schaefer","year":"1991","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0582|cit582","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.jrn.2024.02.005","article-title":"The effect of niacinamide supplementation on phosphate concentrations in Dutch dialysis patients: a randomized crossover trial","volume":"34","author":"Schepers","year":"2024","journal-title":"Journal of Renal Nutrition"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0583|cit583","unstructured":"Sechet A Abi Ghanem O Said S Rasombolobna M Oualim Z Moriniere P Role of administration schedule in relation to meal on CaCO3 efficiency in controlling hyperphosphatemia in dialysis patients [abstract] 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy 1998 38"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0584|cit584","first-page":"209","article-title":"Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis","volume":"20","author":"Sechet","year":"1999","journal-title":"Nephrologie"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0585|cit585","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1046\/j.1525-1594.1998.06199.x","article-title":"Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis","volume":"22","author":"Sechet","year":"1998","journal-title":"Artificial Organs"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0586|cit586","first-page":"213","article-title":"Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis","volume":"20","author":"Sechet","year":"1999","journal-title":"Nephrologie"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0587|cit587","first-page":"140","article-title":"Is sevelamer hydrocloride as effective as calcium carbonate for reduction of serum phosphorus in hemodialysis patients? [abstract]","volume":"16","author":"Seferi","year":"2012","journal-title":"Hemodialysis International"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub4-BIB0588|cit588","first-page":"772","article-title":"The vitamin D therapy alone should be selected in pre-dialysis renal failure patients with secondary hyperparathyroidism, instead of the combination therapy with vitamin D and calcium [abstract no: A4036]","volume":"12","author":"Shigematsu","year":"2001","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0589|cit589","first-page":"887A","article-title":"Lanthanum carbonate is effective enough to control serum P level in line with K\/DOQI target without Ca load in Japanese CKD5 patients undergoing hemodialysis [abstract no: PUB337]","volume":"17","author":"Shigematsu","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0590|cit590","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1744-9987.2007.00541.x","article-title":"Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis","volume":"12","author":"Shigematsu","year":"2008","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0591|cit591","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1159\/000516156","article-title":"Therapeutic effects of add-on tenapanor for hemodialysis patients with refractory hyperphosphatemia","volume":"52","author":"Shigematsu","year":"2021","journal-title":"American Journal of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub4-BIB0592|cit592","first-page":"1807","article-title":"Niceritrol decreases serum phosphate levels in hemodialysis patients - a randomized, double blind, crossover study [abstract no: A2803]","volume":"7","author":"Shimoda","year":"1996","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0593|cit593","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ndt\/gfs405","article-title":"Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial","volume":"28","author":"Sigrist","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0594|cit594","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.ki.5001932","article-title":"Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy","volume":"71","author":"Altmann","year":"2007","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0595|cit595","first-page":"272A","article-title":"Lanthanum carbonate has shown no negative effects on cognitive function compared with standard therapy: results from a 2-year study [abstract no: F-PO950]","volume":"15","author":"Altmann","year":"2004","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub4-BIB0596|cit596","first-page":"v86","article-title":"25-hydroxyvitamin D and 1,25-dihydroxyvitamin D deficiency in stage V chronic kidney disease patients on hemodialysis [abstract no: SP201]","volume":"20","author":"Finn","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0597|cit597","first-page":"765A","article-title":"Lanthanum carbonate versus standard therapy: effects on hematological and biochemical parameters [abstract no: SA-PO951]","volume":"16","author":"Finn","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0598|cit598","first-page":"764","article-title":"No evidence for hepatotoxicity after 2 years of lanthanum carbonate therapy [abstract no: SA-PO950]","volume":"16","author":"Finn","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub4-BIB0599|cit599","first-page":"686","article-title":"A long-term (2-year) assessment of the safety and efficacy of lanthanum carbonate (fosrenol), a non-calcium, non-aluminium phosphate binder for the treatment of hyperphosphataemia [abstract no: W438]","volume":"18","author":"Finn","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub4-BIB0600|cit600","first-page":"764A","article-title":"Lanthanum carbonate vs. standard therapy in hyperphosphatemia: interim findings from a 2-year safety and outcomes study [abstract no: SU-PO1040]","volume":"14","author":"Finn","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0601|cit601","first-page":"A29","article-title":"Lanthanum carbonate (FosrenolTM), a novel phosphate binder, is safe and effective in the long term treatment of hyperphosphatemia in end-stage renal disease [abstract no: PS1-21]","volume":"8","author":"Finn","year":"2003","journal-title":"Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub4-BIB0602|cit602","first-page":"763A","article-title":"The new phosphate-binding agent lanthanum carbonate: further evidence of long-term (2-year) efficacy and safety [abstract no: PUB006]","volume":"15","author":"Finn","year":"2004","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0603|cit603","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CNP65191","article-title":"Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients","volume":"65","author":"Finn","year":"2006","journal-title":"Clinical Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub4-BIB0604|cit604","first-page":"A297","article-title":"A 2-year randomized, comparator-controlled trial investigating the effect of lanthanum carbonate on bone [abstract no: W-PO40066]","volume":"10","author":"Malluche","year":"2005","journal-title":"Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub4-BIB0605|cit605","first-page":"271A","article-title":"Lanthanum carbonate and bone: no adverse effects observed after 1 year of treatment in a randomized, comparator-controlled trial [abstract no: F-PO945]","volume":"15","author":"Malluche","year":"2004","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0606|cit606","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1053\/j.ajkd.2007.02.139","article-title":"Lanthanum carbonate vs standard phosphate binder therapy: evolution of renal osteodystrophy over 1 and 2 years of treatment [abstract no: 133]","volume":"49","author":"Malluche","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0607|cit607","first-page":"359A","article-title":"Renal osteodystrophy: comparison of evolution over 1 and 2 years during treatment with lanthanum carbonate or standard phosphate binders [abstract no: F-PO107]","volume":"17","author":"Malluche","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0608|cit608","first-page":"284","article-title":"Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years","volume":"70","author":"Malluche","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub4-BIB0609|cit609","first-page":"vi171","article-title":"Is 1 year sufficient to observe changes in renal osteodystrophy? Evaluation of serial bone biopsies [abstract no: FP450]","volume":"22","author":"Pratt","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub4-BIB0610|cit610","first-page":"320A","article-title":"Retrospective outcomes analyses of a 2-year comparative study of lanthanum carbonate vs standard therapy [abstract no: TH-PO928]","volume":"19","author":"Wilson","year":"2008","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub4-BIB0611|cit611","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1185\/03007990903399398","article-title":"Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy","volume":"25","author":"Wilson","year":"2009","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0612|cit612","doi-asserted-by":"publisher","first-page":"2050312118","DOI":"10.1177\/2050312118786161","article-title":"Iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders: Results from a phase 3, randomized open-label study","volume":"6","author":"Wilson","year":"2018","journal-title":"SAGE Open Medicine"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0613|cit613","unstructured":"Krause R Sprague S Zhang P Qiu P Ross E Lanthanum carbonate provides greater phosphate reduction than sevelamer hydrochloride over a 4 week treatment period in patients on dialysis [abstract no: SU579] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0614|cit614","first-page":"368A","article-title":"Greater reduction of serum phosphorus with lanthanum carbonate compared with sevelamer hydrochloride in hemodialysis patients [abstract no: F-PO1111]","volume":"20","author":"Sprague","year":"2009","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0615|cit615","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5414\/CNP72252","article-title":"Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study","volume":"72","author":"Sprague","year":"2009","journal-title":"Clinical Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub4-BIB0616|cit616","first-page":"721A","article-title":"Nested cross-sectional analysis of baseline date from the Sevelamer hydrochloride and Ultrasound-Measured femoral and carotid intima Media thickness progression in End stage Renal disease: SUMMER [abstract no: SA-PO2704]","volume":"19","author":"Boaz","year":"2008","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0617|cit617","doi-asserted-by":"publisher","first-page":"449","DOI":"10.5414\/CN108067","article-title":"C-reactive protein and carotid and femoral intima media thickness: predicting inflammation","volume":"80","author":"Boaz","year":"2013","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0618|cit618","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5414\/CN108067","article-title":"C-reactive protein and carotid and femoral intima media thickness: predicting inflammation","volume":"80","author":"Boaz","year":"2013","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0619|cit619","first-page":"c83","article-title":"Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients","volume":"117","author":"Boaz","year":"2011","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0620|cit620","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2215\/CJN.10941016","article-title":"Two phosphAte taRGets in End-stage renal disease Trial (TARGET): a randomized controlled trial","volume":"12","author":"Wald","year":"2017","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0621|cit621","first-page":"472","article-title":"Phosphate binder therapy with sucroferric oxyhydroxide reduces calcification propensity in hemodialysis patients: results from a randomized, controlled, crossover trial [abstract no: FR-PO149]","volume":"30","author":"Cejka","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0622|cit622","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.20203110S1164d","article-title":"The effect of phosphate lowering using sucroferric oxyhydroxide on endogenous calciprotein particle formation in dialysis patients: Post hoc analysis of a randomized controlled trial [abstract no: PO0378]","volume":"31","author":"Thiem","year":"2020","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0623|cit623","doi-asserted-by":"publisher","first-page":"iii1631","DOI":"10.1093\/ndt\/gfaa142.P1308","article-title":"P1308 Phosphate-lowering using sucroferric oxyhydroxide: calcification propensity (T50) in hemodialysis patients. post-hoc analyses of a randomized, controlled clinical trial [abstract]","volume":"35","author":"Thiem","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0624|cit624","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/ckj\/sfaa154","article-title":"The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial","volume":"14","author":"Thiem","year":"2021","journal-title":"Clinical Kidney Journal"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0625|cit625","doi-asserted-by":"publisher","first-page":"1361778","DOI":"10.3389\/fpubh.2024.1361778","article-title":"Effect of a transtheoretical model-based intervention and motivational interviewing on hyperphosphatemia management via telehealth (TMT program) among hemodialysis patients during the COVID-19 pandemic","volume":"12","author":"Thongsunti","year":"2024","journal-title":"Frontiers in Public Health"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0626|cit626","unstructured":"Tielemans C Knoop C Doutrelepont JM Timmermans D Even-Adin D Superiority of calcium acetate (ACET) over carbonate (carb) to bind phosphorous (P) in hemodialysis patients [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0627|cit627","doi-asserted-by":"publisher","first-page":"e0241435","DOI":"10.1371\/journal.pone.0241435","article-title":"Effects of calcium-containing phosphate binders on cardiovascular events and mortality in predialysis CKD stage 5 patients","volume":"15","author":"Tsai","year":"2020","journal-title":"PLOS One [Electronic Resource]"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0628|cit628","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11255-007-9300-0","article-title":"Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial","volume":"40","author":"Tzanakis","year":"2008","journal-title":"International Urology & Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0629|cit629","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/039463201402700105","article-title":"Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis","volume":"27","author":"Tzanno-Martins","year":"2014","journal-title":"International Journal of Immunopathology & Pharmacology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0630|cit630","first-page":"973A","article-title":"High ferritin levels achieved with ferric citrate as phosphate binder do not associate with adverse events [abstract no: PUB368]","volume":"26","author":"Bhatt","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0631|cit631","doi-asserted-by":"publisher","first-page":"iii270","DOI":"10.1093\/ndt\/gfv180.42","article-title":"FP590 Ferric citrate (FC) as a phosphate binder in peritoneal dialysis (PD) [abstract]","volume":"30","author":"Dana","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0632|cit632","first-page":"817A","article-title":"48 week open label safety extension study with ferric citrate demonstrates favorable safety profile in subjects not on intravenous iron: a post-hoc analysis [abstract no: SA-PO813]","volume":"26","author":"Foote","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0633|cit633","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/hdi.12487","article-title":"Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis","volume":"21","author":"Jalal","year":"2017","journal-title":"Hemodialysis International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0634|cit634","doi-asserted-by":"crossref","first-page":"A45","DOI":"10.1053\/j.ajkd.2015.02.123","article-title":"Adherence rates and predictors of adherence to ferric citrate as compared to active control in end stage kidney disease [abstract]","volume":"65","author":"Jalal","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0635|cit635","first-page":"751","article-title":"Ferric citrate binds phosphorus, delivers iron, and reduces IV iron and erythropoietic stimulating agent use in end-stage renal disease [abstract no: SA-PO542]","volume":"24","author":"Lewis","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0636|cit636","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0637|cit637","first-page":"90A","article-title":"Ferric citrate, a phosphate binder, increases iron stores but is not associated with evidence of the malnutrition-inflammation-cachexia syndrome [abstract no: SA-OR083]","volume":"24","author":"Middleton","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0638|cit638","first-page":"880A","article-title":"Ferric citrate (phosphate binder): effects on serum iron and other parameters in ESRD patients [abstract no: PUB306]","volume":"17","author":"Niecestro","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0639|cit639","unstructured":"Niecestro RM Ferric citrate for the treatment of hyperphosphatemia in ESRD [abstract no: S-PO-0416] 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 161"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0640|cit640","doi-asserted-by":"crossref","first-page":"A118","DOI":"10.1053\/j.ajkd.2014.01.438","article-title":"Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs [abstract]","volume":"63","author":"Rodby","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0641|cit641","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1586\/14737167.2015.995169","article-title":"Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs","volume":"15","author":"Rodby","year":"2015","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0642|cit642","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40268-015-0103-y","article-title":"Ferric citrate, an iron-based phosphate binder, reduces health care costs in patients on dialysis based on randomized clinical trial data","volume":"15","author":"Rodby","year":"2015","journal-title":"Drugs in R & D"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0643|cit643","doi-asserted-by":"crossref","first-page":"A102","DOI":"10.1053\/j.ajkd.2014.01.351","article-title":"Oral ferric citrate (FC) eliminates the need for intravenous (IV) iron in dialysis patients [abstract]","volume":"63","author":"Sika","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0644|cit644","doi-asserted-by":"crossref","first-page":"A78","DOI":"10.1053\/j.ajkd.2015.02.257","article-title":"Iron stores are increased within the first 24 weeks and maintained for 80 additional weeks with longterm use of oral ferric citrate (FC) as a phosphate binder [abstract]","volume":"65","author":"Sika","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0645|cit645","first-page":"751A","article-title":"Ferric citrate as a phosphate binder has a safety profile similar to sevelamer carbonate and calcium acetate [abstract no: SA-PO540]","volume":"24","author":"Sika","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0646|cit646","first-page":"221A","article-title":"Ferric citrate as a phosphate binder reduces IV iron and erythropoietin stimulating agent (ESA) use [abstract no: TH-PO521]","volume":"24","author":"Umanath","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0647|cit647","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5414\/CN108924","article-title":"The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis","volume":"87","author":"Umanath","year":"2017","journal-title":"Clinical Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0648|cit648","first-page":"816A","article-title":"Achieved iron stores and clinical safety in a trial of ferric citrate as a phosphate binder [abstract no: SA-PO810]","volume":"26","author":"Umanath","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0649|cit649","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1681\/ASN.2014080842","article-title":"Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD","volume":"26","author":"Umanath","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0650|cit650","first-page":"310A","article-title":"Achieved iron stores and clinical efficacy in a trial of ferric citrate as a phosphate binder [abstract no: TH-PO937]","volume":"26","author":"Umanath","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub4-BIB0651|cit651","first-page":"713A","article-title":"Achieved iron stores and clinical outcomes in a trial of ferric citrate as a phosphate binder [abstract no: SA-PO382]","volume":"24","author":"Umanath","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0652|cit652","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1542-4758.2012.00711.x","article-title":"Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis","volume":"17","author":"Umanath","year":"2013","journal-title":"Hemodialysis International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0653|cit653","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.ajkd.2015.03.013","article-title":"The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial","volume":"66","author":"Van Buren","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0654|cit654","first-page":"752a","article-title":"Impact of ferric citrate, an oral phosphate binder, on mineral and bone metabolism markers in dialysis patients [abstract no: SA-PO543]","volume":"24","author":"Weiner","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0655|cit655","first-page":"505","article-title":"Comparison of three formulations of calcium acetate tablets to evaluate tolerance and control of hyperphosphatemia in patients with chronic renal failure","volume":"68","author":"den Bergh","year":"1994","journal-title":"Nephron"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0656|cit656","first-page":"A60","article-title":"Lanthanum carbonate allows for a lower tablet burden to control serum phosphorus levels [abstract no: 167]","volume":"47","author":"Vemuri","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0657|cit657","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s40620-024-02024-4","article-title":"Education and cooking methods in the management of calcium and PTH serum levels in patients on hemodialysis: a randomized controlled study","volume":"37","author":"Vrdoljak","year":"2024","journal-title":"Journal of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0658|cit658","doi-asserted-by":"publisher","first-page":"100384","DOI":"10.1016\/j.xkme.2021.10.002","article-title":"Long-term effects of sevelamer on vascular calcification, arterial stiffness, and calcification propensity in patients receiving peritoneal dialysis: the randomized pilot SERENE (sevelamer on vascular calcification, arterial stiffness) trial","volume":"4","author":"Wang","year":"2022","journal-title":"Kidney Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0659|cit659","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/1744-9987.12178","article-title":"Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients","volume":"18","author":"Wei","year":"2014","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0660|cit660","first-page":"47A","article-title":"Skeletal response to phosphate binders and intermittent oral vitamin D in dialyzed children with secondary hyperparathyroidism [abstract no: F-FC044]","volume":"16","author":"Hernandez","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0661|cit661","first-page":"739A","article-title":"Comparison between first and second generation PTH assays as predictors of bone turnover during treatment of secondary hyperparathyroidism in dialyzed children [abstract no: SA-PO833]","volume":"16","author":"Salusky","year":"2005","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub4-BIB0662|cit662","first-page":"279A","article-title":"Similar predictive value of bone turnover by first and second generation PTH assays during treatment of secondary hyperparthyroidism in dialyzed children [abstract no: F-PO980]","volume":"15","author":"Wesseling","year":"2004","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0663|cit663","doi-asserted-by":"crossref","first-page":"A27","DOI":"10.1053\/j.ajkd.2012.02.058","article-title":"Iron-based phosphate binder PA21: Effective and well tolerated in CKD hemodialysis patients [abstract]","volume":"59","author":"Chonchol","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0664|cit664","first-page":"146a","article-title":"PA21, a novel oral iron based phosphate binder (PB), significantly reduces hyperphosphatemia in hemodialysis (HD) patients [abstract no: THPO154]","volume":"21","author":"Tumlin","year":"2010","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0665|cit665","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients","volume":"8","author":"Wuthrich","year":"2013","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0666|cit666","first-page":"iii230","article-title":"The effect of PA21, an oral iron based phosphate binder, on the reduction of hyperphosphatemia in hemodialysis-dependent chronic kidney disease (HD-CKD) patients [abstract no: Sa563]","volume":"3","author":"Wuthrich","year":"2010","journal-title":"NDT Plus"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub4-BIB0667|cit667","first-page":"ii153","article-title":"PA21: An effective and well tolerated iron-based phosphate binder for haemodialysis patients, including those with diabetes [abstract no: FP242]","volume":"27","author":"Wuthrich","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0668|cit668","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2369-14-29","article-title":"Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China","volume":"14","author":"Xu","year":"2013","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0669|cit669","unstructured":"Yang WC Yang CS Hou CC Wu TH Cheng YR Young EW An open-label, crossover study of a new phosphate binding agent in hemodialysis patients: ferric citrate [abstract] 8th Asian Pacific Congress of Nephrology; 2000 Mar 26-30; Taipei, Taiwan 2000 187"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0670|cit670","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/17.2.265","article-title":"An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate","volume":"17","author":"Yang","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0671|cit671","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000344008","article-title":"Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Yokoyama","year":"2012","journal-title":"American Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006023.pub4-BIB0672|cit672","first-page":"472","article-title":"Effect of dietary phosphate, binder, and pill burden on phosphate control in dialysis patients [abstract no: FR-PO150]","volume":"30","author":"Zamora-Olivencia","year":"2019","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0673|cit673","doi-asserted-by":"crossref","first-page":"31","DOI":"10.14715\/cmb\/2020.66.2.4","article-title":"Effect of calcitriol combined with sevelamer carbonate on serum parathyroid hormone in patients with chronic renal failure","volume":"66","author":"Zheng","year":"2020","journal-title":"Cellular and Molecular Biology"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0674|cit674","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1093\/ndt\/gfae053","article-title":"Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis","volume":"39","author":"Zhuang","year":"2024","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0675|cit675","unstructured":"Efficacy and safety study of magnesium iron hydroxycarbonate for the reduction of high blood phosphate in hemodialysis patients https:\/\/www.clinicalTrials.gov\/show\/NCT00317694"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0676|cit676","unstructured":"Regulation of bone formation in renal osteodystrophy https:\/\/www.clinicaltrials.gov\/show\/NCT00560300"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0677|cit677","unstructured":"Pragmatic randomised trial of high or standard PHosphAte Targets in end-stage kidney disease (PHOSPHATE) https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03573089"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0678|cit678","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1186\/s13063-022-06562-9","article-title":"Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease","volume":"23","author":"Vermeulen","year":"2022","journal-title":"Trials"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0679|cit679","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/nep.14011","article-title":"Systematic review and meta-analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: beyond phosphate control","volume":"27","author":"Basutkar","year":"2022","journal-title":"Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0680|cit680","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub4-BIB0681|cit681","doi-asserted-by":"crossref","first-page":"e6942","DOI":"10.5867\/medwave.2017.6942","article-title":"Sevelamer versus calcium-based phosphate binders for chronic kidney disease?","volume":"17","author":"Bravo-Soto","year":"2017","journal-title":"Medwave"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0682|cit682","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jarr.2003.50016","article-title":"Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients","volume":"10","author":"Burke","year":"2003","journal-title":"Advances in Renal Replacement Therapy"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0683|cit683","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/ASN.2012070719","article-title":"Cardiovascular effects of sevelamer in stage 3 CKD","volume":"24","author":"Chue","year":"2013","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0684|cit684","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1523-1755.2005.00421.x","article-title":"Pathogenesis of vascular calcification in chronic kidney disease","volume":"68","author":"Cozzolino","year":"2005","journal-title":"Kidney International"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0685|cit685","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1681\/ASN.2020020151","article-title":"GFR in healthy aging: an individual participant data meta-analysis of iohexol clearance in European population-based cohorts","volume":"31","author":"Eriksen","year":"2020","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"7650","key":"10.1002\/14651858.CD006023.pub4-BIB0686|cit686","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0687|cit687","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0688|cit688","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1440-1797.2011.01482.x","article-title":"Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost","volume":"16","author":"Gray","year":"2011","journal-title":"Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0689|cit689","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Guti\u00e9rrez","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0690|cit690","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0691|cit691","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfw312","article-title":"The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"32","author":"Habbous","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0692|cit692","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008327.pub2","article-title":"Interventions for metabolic bone disease in children with chronic kidney disease","author":"Hahn","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD006023.pub4-BIB0693|cit693","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0694|cit694","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0695|cit695","unstructured":"Higgins JP Eldridge S Chapter 23: including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0696|cit696","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"Hruska","year":"2008","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0697|cit697","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1096\/fj.10-154765","article-title":"Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule","volume":"24","author":"Hu","year":"2010","journal-title":"FASEB Journal"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0698|cit698","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1093\/ndt\/gfp350","article-title":"The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis","volume":"24","author":"Jamal","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9900","key":"10.1002\/14651858.CD006023.pub4-BIB0699|cit699","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD006023.pub4-BIB0700|cit700","first-page":"70","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"113","key":"10.1002\/14651858.CD006023.pub4-BIB0701|cit701","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","journal-title":"Kidney International. Supplement"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0702|cit702","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney International. Supplement"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0703|cit703","first-page":"1","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Glogal Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney International. Supplement"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0704|cit704","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0705|cit705","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000505717","article-title":"Aortic calcification and arterial stiffness burden in a chronic kidney disease cohort with high cardiovascular risk: baseline characteristics of the impact of phosphate reduction on vascular end-points in chronic kidney disease trial","volume":"51","author":"Lioufas","year":"2020","journal-title":"American Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0706|cit706","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1681\/ASN.2021040554","article-title":"Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD","volume":"33","author":"Lioufas","year":"2022","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0707|cit707","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","article-title":"A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States","volume":"66","author":"Manns","year":"2004","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0708|cit708","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1681\/ASN.2014101034","article-title":"Cause-specific deaths in non-dialysis-dependent CKD","volume":"26","author":"Navaneethan","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0709|cit709","unstructured":"National Institute of Diabetes Mineral & bone disorder in chronic kidney disease www.niddk.nih.gov\/health-information\/kidney-disease\/mineral-bone-disorder 2024"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0710|cit710","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005015.pub3","article-title":"Interventions for preventing bone disease in kidney transplant recipients","author":"Palmer","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub4-BIB0711|cit711","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.ajkd.2016.05.015","article-title":"Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized controlled trials","volume":"68","author":"Palmer","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0712|cit712","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005015.pub4","article-title":"Interventions for preventing bone disease in kidney transplant recipients","author":"Palmer","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0713|cit713","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2215\/CJN.06800615","article-title":"Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials","volume":"11","author":"Patel","year":"2016","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0714|cit714","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40620-021-01065-3","article-title":"The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials","volume":"35","author":"Phannajit","year":"2022","journal-title":"Journal of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0715|cit715","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.ki.5001997","article-title":"A new era in phosphate binder therapy: what are the options?","volume":"105","author":"Salusky","year":"2006","journal-title":"Kidney International. Supplement"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0716|cit716","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available at www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0717|cit717","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0718|cit718","doi-asserted-by":"crossref","first-page":"e0156891","DOI":"10.1371\/journal.pone.0156891","article-title":"Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"11","author":"Sekercioglu","year":"2016","journal-title":"PLOS One"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0719|cit719","doi-asserted-by":"crossref","first-page":"e0171028","DOI":"10.1371\/journal.pone.0171028","article-title":"Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: a systematic review and NMA","volume":"12","author":"Sekercioglu","year":"2017","journal-title":"PLOS One"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub4-BIB0720|cit720","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1161\/CIRCRESAHA","article-title":"Arterial calcification in chronic kidney disease: key roles for calcium and phosphate","volume":"109","author":"Shanahan","year":"2011","journal-title":"Circulation Research"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0721|cit721","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CNP63119","article-title":"Cellular and molecular mechanisms of secondary hyperparathyroidism","volume":"63","author":"Silver","year":"2005","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0722|cit722","unstructured":"The SONG handbook version 1.0; 1 June 2017 songinitiative.org\/reports-and-publications\/ (accessed 30 November 2024)"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0723|cit723","unstructured":"Standardised Outcomes in Nephrology - Peritoneal Dialysis (SONG-PD) https:\/\/songinitiative.org\/projects\/song-pd\/"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0724|cit724","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.ekir.2021.05.012","article-title":"Phosphate balance and CKD-mineral bone disease","volume":"6","author":"Sprague","year":"2021","journal-title":"Kidney International Reports"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub4-BIB0725|cit725","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2215\/CJN.04100609","article-title":"Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data","volume":"4","author":"St Peter","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0726|cit726","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40265-017-0758-5","article-title":"A review of phosphate binders in chronic kidney disease: incremental progress or just higher costs?","volume":"77","author":"St Peter","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0727|cit727","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/j.ajkd.2017.09.007","article-title":"Phosphate-binder use in US dialysis patients: prevalence, costs, evidence, and policies","volume":"71","author":"St Peter","year":"2018","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0728|cit728","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"Stevens","year":"2004","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0729|cit729","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub4-BIB0730|cit730","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/ndt\/gfm421","article-title":"Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients","volume":"22","author":"Tonelli","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0731|cit731","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/jbmr.3294","article-title":"Impaired phosphate tolerance revealed with an acute oral challenge","volume":"33","author":"Turner","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0732|cit732","unstructured":"Costs of ESRD www.usrds.org\/2009\/pdf\/V2_11_09.pdf"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub4-BIB0733|cit733","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/toxins11110647","article-title":"FGF23 and phosphate-cardiovascular toxins in CKD","volume":"11","author":"Vogt","year":"2019","journal-title":"Toxins"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub4-BIB0734|cit734","doi-asserted-by":"crossref","first-page":"e0133938","DOI":"10.1371\/journal.pone.0133938","article-title":"New conclusions regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2015","journal-title":"PLOS One"},{"issue":"7644","key":"10.1002\/14651858.CD006023.pub4-BIB0735|cit735","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006023.pub4-BIB0736|cit736","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1681\/ASN.2014040325","article-title":"Soluble klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate","volume":"26","author":"Xie","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0737|cit737","first-page":"c259","article-title":"Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients","volume":"115","author":"Zhang","year":"2010","journal-title":"Nephron"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub4-BIB0738|cit738","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.21037\/apm-21-1943","article-title":"Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Zhao","year":"2022","journal-title":"Annals of Palliative Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub4-BIB0739|cit739","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4314\/ahs.v18i3.27","article-title":"A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis","volume":"18","author":"Zhou","year":"2018","journal-title":"African Health Sciences"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub4-BIB0740|cit740","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12882-018-1094-z","article-title":"The role of klotho in chronic kidney disease","volume":"19","author":"Zou","year":"2019","journal-title":"BMC Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0741|cit741","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006023","article-title":"Phosphate binders for preventing and treating bone disease in chronic kidney disease patients","author":"Navaneethan","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub4-BIB0742|cit742","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006023.pub2","article-title":"Phosphate binders for preventing and treating bone disease in chronic kidney disease patients","author":"Navaneethan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub4-BIB0743|cit743","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006023.pub3","article-title":"Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)","author":"Ruospo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:23:59Z","timestamp":1786609439000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006023.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":743,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006023.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}